



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
 International Bureau


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 15/12, 15/67, 15/85, 5/10, C07K 14/505, A01K 67/027		(11) International Publication Number: WO 96/19573
A1		(43) International Publication Date: 27 June 1996 (27.06.96)
(21) International Application Number: PCT/CA95/00696		(81) Designated States: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG).
(22) International Filing Date: 18 December 1995 (18.12.95)		
(30) Priority Data: 08/358,918 19 December 1994 (19.12.94) US		
(60) Parent Application or Grant (63) Related by Continuation US 08/358,918 (CON) Filed on 19 December 1994 (19.12.94)		
(71) Applicant (for all designated States except US): CANGENE CORPORATION [CA/CA]; 104 Chancellor Matheson Road, Winnipeg, Manitoba R3T 2N2 (CA).		
(72) Inventor; and (75) Inventor/Applicant (for US only): DELCUVE, Geneviève [BE/CA]; 74 McGill Place, Winnipeg, Manitoba R3T 5B2 (CA).		
(74) Agent: BERESKIN & PARR; 40th floor, 40 King Street West, Toronto, Ontario M5H 3Y2 (CA).		Published With international search report.

(54) Title: RECOMBINANT DNA MOLECULES AND EXPRESSION VECTORS FOR ERYTHROPOIETIN

(57) Abstract

A recombinant DNA molecule adapted for transfection of a host cell comprising a nucleic acid molecule encoding mammalian erythropoietin, an expression control sequence operatively linked thereto and at least one SAR element. The invention also relates to expression vectors having the recombinant DNA molecule and to mammalian cells transformed with the expression vector. The mammalian cells lack multiple copies of an amplified amplification gene and are capable of expressing recombinant EPO in vitro at levels of at least 1,500 u/10⁶ cells in 24 hours. The invention further relates to a method of expressing recombinant mammalian erythropoietin using the expression vectors and to a transgenic non-human animal or embryo whose germ cells and somatic cells contain a DNA construct having the recombinant DNA molecule of the invention.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LJ	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

**Title: Recombinant DNA Molecules and
Expression Vectors for Erythropoietin**

FIELD OF THE INVENTION

The invention relates to recombinant DNA molecules
5 adapted for transfection of a host cell, and having a
nucleic acid molecule encoding mammalian erythropoietin,
operatively linked to an expression control sequence and
having at least one SAR element. The invention also
relates to expression vectors for transfection of a host
10 cell and to host cells for expressing erythropoietin.
The invention further relates to methods of preparing
recombinant erythropoietin using the host cells
transfected with the expression vectors.

BACKGROUND OF THE INVENTION

15 Erythropoietin (EPO) is a heavily glycosylated
acidic glycoprotein with a molecular weight of
approximately 35,000. The protein consists of 166 amino
acids and has a leader signal sequence of 27 amino acids
which is removed in vivo during secretion from the host
20 cell. The sequence encoding the unprocessed EPO is 579
nucleotides in length (Jacobs et al, 1985, Lin et al,
1985, U.S. Patent 4,703,008 and WO 86/03520).

Erythropoietin is the principal hormone involved in
the regulation and maintenance of physiological levels of
25 erythrocytes in mammalian circulation and functions to
promote erythroid development, to initiate hemoglobin
synthesis and to stimulate proliferation of immature
erythroid precursors. The hormone is produced primarily
by the adult kidney and foetal liver and is maintained in
30 the circulation at concentrations of about 10-20
milliunits/ml of serum under normal physiological
conditions. Elevated levels of EPO, induced by tissue
hypoxia, trigger proliferation and differentiation of a
population of receptive progenitor stem cells in the bone
35 marrow, stimulating hemoglobin synthesis in maturing

- 2 -

erythroid cells and accelerating the release of erythrocytes from the marrow into the circulation.

Recombinant EPO has been used to successfully treat patients, including patients having anemia as a result of chronic renal failure. As EPO is the primary regulator of red blood cell formation, it has applications in both the diagnosis and treatment of disorders of red blood cell production and has potential applications for treating a range of conditions.

10 The urine of severely anaemic patients was, at one time, almost the sole source for the commercial isolation of EPO. U.S. Patent No. 3,033,753 describes a method for obtaining a crude EPO preparation from sheep plasma. The preparation of monoclonal antibodies specific for human EPO provided a means for identifying EPO produced from EPO mRNA, for screening libraries and for cloning the EPO gene. Human EPO cDNA has been cloned and expressed in E. coli (Lee-Huang, 1984, Proc. Natl. Acad. Sci. 81:2708). Isolation of the human EPO gene using mixtures of short or long synthetic nucleotides as probes led to the expression of biologically active EPO in mammalian cells (Lin, 1985, Proc. Natl. Acad. Sci. 82:7580; Lin, WO 85/02610; Jacobs, et al., 1985, Nature (Lond.) 313:806; Goto et al., 1988, Biotechnology 6:67). Jacobs, et al., 1985, supra, described the use of plasmids containing EPO DNA which were not integrated into the chromosomes of the COS host cells, but replicated autonomously in the cells to many thousands of copies, thereby killing the cells. Thus the expression of EPO was only a transient phenomenon in these cells.

30 Lin, in U.S. Patent No. 4,703,008, reported expression of the human EPO gene in COS-1 and CHO cells. However, attempts to use transfected cells as production vehicles for EPO have been hampered by the low levels of EPO expressed by transfected cells. Given the important applications of recombinant EPO, there is much interest in developing more efficient methods for the expression of

- 3 -

EPO.

- Lin in U.S. Patent No. 4,703,008 reported methods to increase the low amounts of EPO produced by transfected CHO cells (e.g. 2.99u/ml/3 days) by a process of gene amplification. Levels of approximately 1500 units EPO/10⁶ cells/48 hours were reported by Lin, following amplification. Gene amplification involves culturing cells in appropriate media conditions to select cells resistant to a selective agent, such as the drug methotrexate.
- Selection for cells resistant to methotrexate produces cells containing greater numbers of DHFR genes and passenger genes, such as the EPO gene carried on the expression vector along with the DHFR gene or transfected with the DHFR gene.
- However, gene amplification is a very time consuming and labour intensive process. A major disadvantage of amplification is the inherent instability of amplified genes (McDonald, 1990, Crit. Rev. Biotech. 10:155). As it is usually necessary to maintain the amplified cells in the presence of toxic analogs to maintain high copy number, amplification may be inappropriate for large scale production due to the costs and toxicity of the selective agent. The high copy number of the DHFR-target transgene may also sequester transcription factor, leading to a retardation of cell growth.

Genomic clones of human EPO have been used in attempts to develop stably transfected mammalian cell lines that secrete high levels of active erythropoietin (Powell, et al., 1986, Proc. Natl. Acad. Sci. 83:6465; Masatsuga, et al., European Patent Application Publication No. 0 236 059). In PCT Application WO 88/00241 Powell, describes the preparation of mammalian cell lines (COS-7 and BHK) transfected with the Apa I restriction fragment of the human EPO gene and selected for high expression by amplification.

Human EPO cDNA has also been expressed in mammalian cells (Yanagi, et al., 1989, DNA 8: 419). Bernstein, in

- 4 -

PCT application WO 86/03520 describes the expression of EPO cDNA in various host cells, resulting in the secretion of up to 160 ng/ml of EPO into the medium after amplification. European Patent Application publication
5 No. 0 267 678 discloses expression of recombinant EPO and secretion into the culture medium at levels of 600 units/ml.

A few scaffold attachment region (SAR) elements have been shown to increase the expression of reporter genes in
10 transfected cells. SAR elements are thought to be DNA sequences which mediate attachment of chromatin loops to the nuclear matrix or scaffold. SAR elements are also known as MAR (matrix-associated regions) (reviewed by Phi-Van and Strätling, Prog. Mol. Subcell. Biol. 11:1-11,
15 1990). These elements will hereinafter be referred to as "SAR elements". SAR elements are usually 300 or more base pairs long, and they require a redundancy of sequence information and contain multiple sites of protein-DNA interaction. SAR elements are found in non-coding
20 regions: in flanking regions or introns.

Stief, et al., (Nature 341:343-345, 1989) stably transfected chicken macrophage cells by constructs which contained the CAT gene either fused to the lysozyme promoter, or to the lysozyme promoter and the lysozyme
25 enhancer. When the transcription units contained in both constructs were flanked on both sides by lysozyme 5' SAR elements (A elements), gene expression was increased about 10 times relative to transfectants, which contained the constructs lacking the SAR elements.

30 Phi-Van, et al., (Mol. Cell. Biol., 10:2302-2307, 1990) determined the influence of the SAR element located 5' to the chicken lysozyme gene (A element) on the CAT gene expression from a heterologous promoter (herpes simplex virus thymidine kinase promoter) in stably
35 transfected heterologous cells (rat fibroblasts). The median CAT activity per copy number in transfectants was 10 times higher for the transcriptional unit flanked on

- 5 -

both sides by A elements than for the transcriptional unit lacking SAR elements.

Klehr, et al., (Biochemistry, 30:1264-1270, 1991) stably transfected mouse L cells by different constructs
5 containing the human interferon β gene. When the construct was flanked by SAR elements, the gene transcription level was enhanced 20-30 fold with respect to the SAR-free construct, containing only the immediate regulatory elements.

10 However, the above-noted experiments have been limited to a very few examples of SAR elements, expressing mostly reporter genes, such as chloramphenicol acetyl transferase (CAT) or luciferase. SAR elements have not shown consistent results in their effect on the
15 expression of target genes and some target gene sequences have been found to inhibit the effect of SAR elements (Klehr, et al., 1991, Biochemistry 30:1264).

SUMMARY OF THE INVENTION

The present inventor has significantly found that
20 SAR elements may be used to increase the expression of recombinant mammalian EPO DNA. The present inventor constructed expression vectors carrying EPO genomic or cDNA sequences flanked by 3' and 5' human apolipoprotein B SAR elements. The expression vectors, when transfected
25 into host cells resulted in increased expression of EPO compared to control host cells transfected with EPO expression vectors lacking SAR elements. Host cells transfected with expression vectors carrying an EPO cDNA sequence flanked by 3' and 5' SAR elements which expressed
30 high levels of EPO were selected and cloned to obtain homogenous stable cell lines over-expressing EPO. Cloning produced stable cell lines expressing high levels of EPO, without the need for amplification. SAR elements have not, to the inventor's knowledge, heretofore been used for
35 long term expression of a target gene in stable cell lines, or for the expression of recombinant EPO.

The present invention thus provides a recombinant

- 6 -

DNA molecule adapted for transfection of a host cell comprising a nucleic acid molecule encoding mammalian erythropoietin, an expression control sequence operatively linked thereto and at least one SAR element. In an embodiment, the nucleic acid molecule encodes mammalian erythropoietin having the amino acid sequence shown in SEQ ID NOS 33 or 34 and Figure 3B. In another embodiment, the nucleic acid molecule has the sequence as shown in SEQ ID NO. 33 or 35.

10 The SAR element is preferably a SAR element co-mapping with the chromatin domain boundary, such as the human apolipoprotein SAR elements, most preferably the SAR element comprises the sequence as shown in SEQ ID NO. 36 or 37 and Figures 5 or 6.

15 The present invention also provides an expression vector comprising a recombinant DNA molecule adapted for transfection of a host cell comprising a nucleic acid molecule encoding mammalian erythropoietin, an expression control sequence operatively linked thereto and at least one SAR element.

20 In an embodiment, the expression vector comprises a nucleic acid molecule encoding erythropoietin and having the sequence shown in SEQ ID NO. 35 and Figure 4 under the control of the human cytomegalovirus IE enhancer and promoter and the beta-globin intron and, flanked by 5' and 3' apolipoprotein SAR elements.

25 In a further embodiment, the expression vector comprises a nucleic acid molecule encoding erythropoietin and having the sequence shown in SEQ ID NO. 35 and Figure 4, flanked by 5' and 3' apolipoprotein SAR elements under the control of elongation factor - 1 alpha promoter and intron.

30 The present invention still further provides a mammalian cell stably transfected with the expression vector of the invention. The mammalian cell may be any mammalian cell, for example CHO-K1, BHK, Namalwa. An aspect of the invention provides a mammalian cell, lacking

- 7 -

multiple copies of an amplified selectable marker gene and capable of expressing recombinant EPO in vitro at levels of at least 1,500, preferably over 2,000, most preferably from 2,000 to 10,000 u/10⁶ cells in 24 hours.

5 In yet a further aspect, the invention provides a method of expressing recombinant mammalian erythropoietin comprising the steps of culturing a transfected mammalian cell of the invention in a suitable medium until
10 sufficient amounts of erythropoietin are produced by the cell and separating the erythropoietin produced.

The present invention also relates to a method of preparing recombinant erythropoietin comprising
transfecting a mammalian cell with an expression vector comprising a nucleic acid molecule encoding mammalian
15 erythropoietin, an expression control sequence operatively linked thereto and at least one SAR element; culturing the transfected cell in a suitable medium until sufficient
amounts of erythropoietin are produced by the cell and separating the erythropoietin produced. In a preferred
20 embodiment, the erythropoietin is produced at levels of at least 2,000, most preferably from 2,000 to 10,000 u/10⁶ cells in 24 hours in the absence of gene amplification. The invention also relates to erythropoietin produced by the method of the invention.

25 In an embodiment of the method, the mammalian cell is further transfected with a selectable marker gene and transfected cells are selected in conditions where the activity of the product encoded by the selectable marker gene is necessary for survival of the cells. In a
30 preferred embodiment, the selectable marker gene is pSV2neo.

In a further embodiment, the method comprises the additional step of identifying and selecting cells
producing high levels of erythropoietin; cloning the
35 selected cells; establishing long term cell lines from the selected cells and; culturing the selected cells in a suitable medium until sufficient amounts of erythropoietin

- 8 -

are produced by the cell and separating the erythropoietin produced.

The present invention further provides a transgenic non-human animal or embryo whose germ cells and somatic
5 cells contain a DNA construct comprising the recombinant DNA molecule of the invention.

DESCRIPTION OF THE DRAWINGS

The invention will be better understood with reference to the drawings in which:

10 Figure 1A is a schematic representation of the procedure for synthesizing the erythropoietin gene;

Figure 1B shows the DNA sequences of the oligonucleotides synthesized to construct the erythropoietin gene;

15 Figure 2A is a schematic representation of the procedure for synthesizing the EPO_{short} sequence;

Figure 2B is a schematic representation of the procedure for synthesizing the EPO_{long} sequence;

20 Figure 3A shows the DNA sequence of the erythropoietin gene;

Figure 3B shows the amino acid sequence of the mature erythropoietin protein;

Figure 4 shows the DNA sequence of the EPO_{long} sequence;

25 Figure 5 shows the DNA sequence of the 3' SAR element of human apolipoprotein B;

Figure 6 shows the DNA sequence of Rh10;

Figure 7 shows a restriction map of the vector pLW18 and;

30 Figure 8 shows a restriction map of the vector pLW19.

DETAILED DESCRIPTION OF THE INVENTION

As hereinbefore noted, the present inventor has significantly found that recombinant EPO expression is
35 increased in host cells transfected with recombinant DNA encoding EPO operatively linked to an expression control sequence and SAR elements, compared to host cells

- 9 -

transfected with EPO in the absence of SAR elements.

The present invention thus provides a recombinant DNA molecule adapted for transfection of a host cell comprising a nucleic acid molecule encoding mammalian erythropoietin, an expression control sequence operatively linked thereto and at least one SAR element. In a preferred embodiment the EPO is human EPO and in a particularly preferred embodiment the nucleic acid molecule has a sequence which encodes erythropoietin having the amino acid sequence as shown in SEQ ID NO 33 and 34 and Figure 3B. In a particular embodiment, the nucleic acid molecule has the sequence as shown in SEQ ID NOS. 35 or 33.

1. Nucleic Acid Molecules Encoding Erythropoietin

The term "a nucleic acid molecule encoding mammalian EPO" as used herein means any nucleic acid molecule which encodes biologically active EPO. It will be appreciated that, within the context of the present invention, EPO may include various structural forms of the primary protein which retain biological activity. Biologically active EPO will include analogues of EPO having altered activity, for example having greater biological activity than EPO. Biological activity of EPO may be readily determined by the methods referred to herein.

Nucleic acid molecules encoding EPO include any sequence of nucleic acids which encode biologically active EPO, preferably, the nucleic acid molecule also encodes the leader sequence of the prepeptide to permit secretion of EPO from a cell transfected with the recombinant DNA molecule of the invention. The amino acid sequence of the leader sequence of the prepeptide is shown in SEQ ID NO. 33, from amino acid number -27 to -1. In an embodiment, the nucleic acid molecule encodes a peptide having the amino acid sequence as shown in SEQ ID NO. 33 and 34 and Figure 3B. Nucleic acid molecules encoding EPO include the entire EPO gene sequence as shown in SEQ ID NO. 33, one or more fragments of this sequence encoding the EPO

- 10 -

prepeptide (nucleotides 625-637, 1201-1346, 1605-1691, 2303-2482 and 2617-2772 in SEQ ID NO. 33) or the mature EPO peptide (nucleotides 1269-1346, 1605-1691, 2303-2482 and 2617-2769 in SEQ ID NO. 33) or nucleic acid molecules
5 having substantial homology thereto, or any fragment thereof encoding biologically active EPO, such as the EPO_{long} sequence shown in SEQ ID NO. 35 and Figure 4.

It will be appreciated that the invention includes nucleotide or amino acid sequences which have substantial
10 sequence homology with the nucleotide and amino acid sequences shown in SEQ ID NOS: 33, 34 and 35 and Figures 3A, 3B and 4. The term "sequences having substantial sequence homology" means those nucleotide or amino acid sequences which have slight or inconsequential sequence
15 variations from the sequences disclosed in SEQ ID NOS. 33, 34 and 35 i.e. the homologous sequences function in substantially the same manner to produce substantially the same polypeptides as the actual sequences. Due to code degeneracy, for example, there may be considerable
20 variation in nucleotide sequences encoding the same amino acid sequence. The variations may be attributable to local mutations or structural modifications.

It will also be appreciated that a double stranded nucleotide sequence comprising a DNA segment of the
25 invention or an oligonucleotide fragment thereof, hydrogen bonded to a complementary nucleotide base sequence, and an RNA made by transcription of this double stranded nucleotide sequence, are contemplated within the scope of the invention.

30 A number of unique restriction sequences for restriction enzymes are incorporated in the DNA sequence identified in SEQ ID NO: 33, and 35 and in Figures 3A, and 4 respectively, and these provide access to nucleotide sequences which code for polypeptides unique to
35 EPO. DNA sequences unique to EPO or isoforms thereof, can also be constructed by chemical synthesis and enzymatic ligation reactions carried out by procedures known in the

- 11 -

art.

Mutations may be introduced at particular loci for instance by synthesizing oligonucleotides containing a mutant sequence, flanked by restriction sites enabling
5 ligation to fragments of the native sequence. Following ligation, the resulting reconstructed sequence encodes a derivative having the desired amino acid insertion, substitution, or deletion.

Alternatively, oligonucleotide-directed site-
10 specific mutagenesis procedures may be employed to provide an altered gene having particular codons altered according to the substitution, deletion, or insertion required. Deletion or truncation derivatives of EPO may also be constructed by utilizing convenient restriction
15 endonuclease sites adjacent to the desired deletion. Subsequent to restriction, overhangs may be filled in or removed, and the DNA religated. Exemplary methods of making the alterations set forth above are disclosed by Sambrook et al. (Molecular cloning A Laboratory Manual, 2d
20 Ed., Cold Spring Harbor Laboratory Press, 1989).

The scope of the present invention also includes conjugates of EPO along with other molecules such as proteins or polypeptides. This may be accomplished, for example, by the synthesis of N-terminal or C-terminal
25 fusion proteins or fragments of proteins to facilitate purification or identification of EPO (see U.S. Patent No. 4,851,341, see also, Hopp et al., Bio/Technology 6:1204, 1988.) Thus, fusion proteins may be prepared by fusing through recombinant techniques the N-terminal or C-
30 terminal of EPO or other portions thereof, and the sequence of a selected protein with a desired biological function. The resultant fusion proteins contain EPO or a portion thereof fused to the selected protein or portion thereof. Examples of proteins which may be selected to
35 prepare fusion proteins include lymphokines such as gamma interferon, tumor necrosis factor, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, GM-CSF, CSF-1

- 12 -

and G-CSF, nerve growth factor, protein A, protein G, GST and the Fc portion of immunoglobulin molecules.

Nucleic acid molecules encoding EPO may be chemically synthesized or may be cloned from a genomic or
5 cDNA mammalian library using oligonucleotide probes derived from the known EPO sequences following standard procedures. In this manner, nucleic acid molecules encoding EPO may be obtained from the cells of a selected mammal.

10 For example, cDNA sequences encoding mammalian EPO may be isolated by constructing cDNA libraries derived from reverse transcription of mRNA in cells from the selected mammal which express EPO, for example adult kidney cells or foetal liver cells. Increased levels of
15 expression in the cell may also be achieved, for example by inducing anemia in the mammal. DNA oligonucleotide probes may be used to screen the library for positive clones. Genomic DNA libraries may also be constructed and screened by plaque hybridization using fragments of EPO
20 cDNA as probes.

Nucleic acid molecules which encode EPO may also be obtained from a variety of sources, including for example, depositories which contain plasmids encoding EPO sequences including the American Type Culture Collection (ATCC,
25 Rockville Maryland), and the British Biotechnology Limited (Cowley, Oxford England). EPO DNA as described in Lin, (1985, Proc. Natl. Acad. Sci. U.S.A. 82:7580) is deposited as HUMERPA, Accession No M11319.

Various post translational modifications are
30 contemplated to the EPO encoded by the nucleic acid molecule. For example, EPO may be in the form of acidic or basic salts, or in neutral form. In addition, individual amino acid residues may be modified by, for example, oxidation or reduction. Furthermore, various
35 substitutions, deletions, or additions may be made to the amino acid or DNA nucleic acid sequences, the net effect of which is to retain biological activity of EPO.

- 13 -

In a preferred embodiment of the invention, the nucleic acid molecule of the invention comprises the EPO_{long} nucleotide molecule encoding EPO, shown in SEQ ID NO. 35 and Figure 4. EPO_{long} may be chemically synthesized by assembling short nucleotides, for example, as shown in Figure 1B and SEQ ID NOS. 1 to 32. The procedure for the synthesis and assembly of the EPO_{long} sequence from the short nucleotides is shown schematically in Figure 2B.

2. SAR Elements

The term "SAR elements" as used herein refers to DNA sequences having an affinity or intrinsic binding ability for the nuclear scaffold or matrix. SAR elements are usually 300 or more base pairs long, require a redundancy of sequence information and contain multiple sites of protein-DNA interaction. Preferably SAR elements are found in non coding regions: in flanking regions or introns.

Suitable SAR elements for use in the invention are those SAR elements which promote elevated and position-independent gene activity in stable transfectants. SAR elements may be obtained, for example, from eukaryotes including mammals, plants, insects and yeast, preferably mammals. SAR elements are preferably selected which co-map with the boundaries of a chromatin domain. SAR elements co-mapping with the chromatin domain boundary are preferred for the recombinant DNA molecules of the invention to promote the formation of an independent domain containing the nucleic acid molecule encoding mammalian EPO to be expressed in stable transfectants.

Examples of preferred SAR elements which co-map with the chromatin domain boundary include the following: the 5' human apoB SAR element (Rh10), a XbaI fragment spanning nucleotides -5,262 to -2,735 of the human apoB gene, as shown in SEQ ID 37 and Figure 6 and as described in Levy-Wilson and Fortier, 1989, (J. Biol. Chem. 264:21196). This region actually contains two SAR elements, a proximal and distal one. It is contemplated that either the

- 14 -

proximal and distal SAR elements together or the distal element alone may be used. The 3' human apoB SAR element extends between nucleotides +43,186 and +43,850. The DNA sequence of this 665 bp region is described in Levy-Wilson
5 and Fortier, 1989, supra and shown in SEQ ID NO. 36 and Figure 5. A 60-bp deleted 3'human apoB SAR element (Rh32), is also suitable for use in the invention. The deletion is shown within brackets in Figure 5.

Examples of suitable protocols for identifying SAR
10 elements for use in the present invention are described below. The high salt method may be used to identify SAR elements by measuring the ability of labelled naked DNA fragments to bind nuclear matrices in the presence of unlabelled competitor DNA, typically *E. coli* DNA. DNA
15 fragments bound to nuclear matrices under these conditions are operationally defined as SAR elements. The nuclear matrices may be isolated by the 2 M NaCl extraction of DNAase I-digested nuclei (Cockerill and Garrard, 1986, Cell 44, 273-282). Chromosomal loop anchorage of the
20 kappa immunoglobulin gene occurs next to the enhancer in a region containing topoisomerase II sites. (Cockerill, 1990, Nucleic. Acids. Res. 18, 2643-2648).

In the low salt method for identifying SAR elements nuclei are heated to 37°C and then extracted with a buffer
25 containing 25 mM 3,5-diiodosalicylic acid lithium salt (LIS) which removes histones. The LIS-treated nuclei are extracted several times with a low salt buffer. The extracted nuclei are digested with restriction endonucleases. The solubilized (non-matrix bound) DNA
30 fragments are removed by centrifugation. Southern blot hybridization with labelled probes identifies the DNA fragments bound to the nuclear matrix (Mirkovitch et al., 1984, Cell 39, 223-232). Both the above-noted methods yield essentially the same result, that is, a sequence
35 identified as a SAR element with the high salt method will also be identified as a SAR element by the Lis-low salt method.

- 15 -

The SAR element may be inserted into the recombinant molecule of the invention upstream or downstream from the nucleic acid molecule encoding EPO and the operatively linked expression control sequence. Preferably, the SAR element is inserted within 0.1 to 100 kb upstream or downstream, more preferably from 0.1 to 50 kb, most preferably 0.5 to 10. In a preferred embodiment, more than one SAR element should be inserted into the recombinant molecule of the invention, preferably the SAR elements should be located in flanking positions both upstream and downstream from the nucleic acid molecule encoding EPO and the operatively linked expression control sequence. The use of flanking SAR elements in the nucleic acid molecules may allow the SAR elements to form an independent loop or chromatin domain, which is insulated from the effects of neighbouring chromatin. Accordingly, EPO gene expression may be position-independent and the level of expression should be directly proportional to the number of integrated copies of the recombinant DNA molecules of the invention. Preferably, the SAR elements should be inserted in non-coding regions of the recombinant DNA molecule.

The recombinant DNA molecules of the invention may be advantageously used to express elevated levels of mammalian EPO. Routine procedures may be employed to confirm that the SAR elements selected by the above-noted protocols are useful for expressing elevated levels of mammalian EPO. For example, appropriate expression vectors comprising a nucleic acid molecule encoding mammalian erythropoietin and an expression control sequence operatively linked thereto may be constructed with and without (control vectors) SAR elements. Mammalian host cells may be stably transfected with an EPO expression vector having a selectable marker gene or may be stably co-transfected with an EPO expression vector and a selectable marker gene vector, such as a pSV2-neo vector (which carries the gene conferring the resistance

- 16 -

to the antibiotic G-418). The levels of EPO secreted may be determined, for example, by RIA and the effect of the flanking SAR elements on EPO production may be determined. Transfected cell populations producing the highest levels of EPO as detected by RIA, may be selected and subjected to successive rounds of cloning by the dilution method.

3. Expression Control Sequences

Suitable expression control sequences may be derived from a variety of mammalian sources. Selection of appropriate regulatory elements is dependent on the host cell chosen, and may be readily accomplished by one of ordinary skill in the art. Examples of regulatory elements include: a transcriptional promoter and enhancer or RNA polymerase binding sequence, splice signals, polyadenylation signals, including a translation initiation signal. Additionally, depending on the host cell chosen and the vector employed, other genetic elements, such as an origin of replication, additional DNA restriction sites, enhancers, sequences conferring inducibility of transcription, and selectable markers, may be incorporated into the expression vector.

Strong promoters (or enhancer/promoters) are preferably selected. A strong promoter is one which will direct the transcription of a gene whose product is abundant in the cell. The relative strength and specificities of a promoter/enhancer may be compared in comparative transient transfection assays. In an embodiment, a promoter may be selected which has little cell-type or species preference and which can therefore be strong when transfected into a variety of cell types.

In preferred embodiments of the invention, the EF1 promoter or the human cytomegalovirus (hCMV) IE (immediate-early) enhancer and promoter may be used. The human EF-1 α gene promoter is stronger than the adenovirus major late promoter in a cell free system (Uetsuki et al., 1989, J. Biol. Chem. 264:5791). The EF1 promoter is the promoter for the human chromosomal gene for the

- 17 -

polypeptide chain elongation factor-1 α : extending from -303 to -1 for genomic constructs and from -303 to +986 for cDNA constructs. For the cDNA constructs, the EF1 DNA sequence includes the promoter as well as exon 1 and
5 intron 1 (Uetsuki et al, 1989, J. Biol. Chem. 264, 5791-5798). The human cytomegalovirus (hCMV) IE (immediate-early) enhancer and promoter, extend from -598 to +54 in the sequence (Kay and Humphries, 1991, Methods in Molecular and Cellular Biology 2, 254-265).

10 4. Methods of Expressing EPO

As hereinbefore noted, the present invention also provides expression vectors which include the recombinant DNA molecule of the invention and mammalian cells stably transfected with the expression vector.

15 Suitable expression vectors, such as plasmids, bacteriophage, retroviruses and cosmids are known in the art. Many plasmids suitable for transfecting host cells are well known in the art, including among others, pBR322 (see Bolivar et al., Gene 2:9S, 1977), the pUC plasmids
20 pUC18, pUC19, pUC118, pUC119 (see Messing, Meth in Enzymology 101:20-77, 1983 and Vieira and Messing, Gene 19:259-268, 1982), and pNH8A, pNH16a, pNH18a, and Bluescript M13 (Stratagene, La Jolla, Calif.). Retroviral vectors are reviewed in Eglitis and Anderson, 1988,
25 Biotechniques 6:608. Suitable expression vectors are those which are stably incorporated into the chromosome of the mammalian host cell.

The recombinant DNA molecule of the invention may be expressed by a wide variety of mammalian cells. Methods
30 for transfecting such cells to express foreign DNA are well known in the art (see, e.g., Itakura et al., U.S. Patent No. 4,704,362; Hinnen et al., PNAS USA 75:1929-1933, 1978; Murray et al., U.S. Patent No. 4,801,542; Upshall et al., U.S. Patent No. 4,935,349; Hagen et al.,
35 U.S. Patent No. 4,784,950; Axel et al., U.S. Patent No. 4,399,216; Goeddel et al., U.S. Patent No. 4,766,075; and Sambrook et al. Molecular Cloning A Laboratory Manual, 2nd

- 18 -

edition, Cold Spring Harbor Laboratory Press, 1989, all of which are incorporated herein by reference). Suitable expression vectors include vectors having a selectable marker gene.

5 Mammalian cells suitable for carrying out the present invention include, among others: COS (e.g., ATCC No. CRL 1650 or 1651), BHK (e.g., ATCC No. CRL 6281), CHO-K1 (ATCC No. CCL 61), HeLa (e.g., ATCC No. CCL 2), 293 (ATCC No. 1573) and NS-1 cells. As noted above, suitable
10 expression vectors for directing expression in mammalian cells generally include a promoter, as well as other transcriptional and translational control sequences. Common promoters include SV40, MMTV, metallothionein-1, adenovirus Ela, CMV, immediate early, immunoglobulin heavy
15 chain promoter and enhancer, human cytomegalovirus 1E enhancer and promoter and RSV-LTR. Protocols for the transfection of mammalian cells are well known to those of ordinary skill in the art. Representative methods include calcium phosphate mediated gene transfer, electroporation,
20 retroviral, and protoplast fusion-mediated transfection (see Sambrook et al., supra).

Given the teachings provided herein, promoters, terminators, and methods for introducing expression vectors of an appropriate type into mammalian cells may be
25 readily accomplished. Accordingly, the invention also relates to mammalian cells stably transfected with an expression vector of the invention. The term "stably transfected" refers to the fact that suitable expression vectors are those which stably incorporate the recombinant
30 DNA molecule of the invention into the chromosomes of the mammalian cell.

The invention also relates to a mammalian cell lacking a selectable marker gene capable of being amplified and, capable of expressing recombinant EPO in
35 vitro at levels of at least 1,500, preferably at least 2,000, most preferably 2,000 to 10,000 u/10⁶ cells in 24 hours.

- 19 -

In an embodiment, the invention also relates to a mammalian cell, having less than 1,000, preferably less than 100, most preferably less than 10 copies of a selectable marker gene and capable of expressing
5 recombinant EPO in vitro at levels of at least 1,500, preferably at least 2,000, most preferably 2,000 to 10,000 u/10⁶ cells in 24 hours.

Amplification refers, for example, to the process of culturing cells in appropriate medium conditions to
10 select cells resistant to the drug methotrexate. Such cells have been found to be resistant to methotrexate due to an amplification of the number of their gene encoding dihydrofolate reductase (DHFR). Selection for cells resistant to methotrexate produces cells containing
15 greater numbers of DHFR genes. Passenger genes, such as the EPO gene carried on the expression vector along with the DHFR gene or co-transfected with the DHFR gene may also be increased in their gene copy number. Cells which have been amplified thus have multiple copies of the
20 selectable marker gene in addition to the passenger gene.

It is an advantage of the present invention that high levels of EPO expression may be achieved without the need for amplification. Thus the mammalian cells of the invention express high levels of EPO and do not express
25 high levels of a selectable marker gene. The expression of high levels of selectable marker genes in amplified cells may interfere with the cell's ability to remain stable in long term culture and to express high levels of EPO in long term culture. Amplified cells may carry
30 certain disadvantages such as non-specific toxicity associated with exposure of the cells to the inhibitory drug or compound.

Selectable marker genes which may be amplified in a mammalian host cell are known in the art and include the
35 genes encoding proteins conferring resistance to chloramphenicol (Wood et al., CSHSQB 51:1027, 1986), methotrexate (Miller, MC Biol., 5:431, 1985; Corey et al.,

- 20 -

Blood 75:337, 1990; Williams et al., Proc. Natl. Acad. Sci. USA, 83:2566, 1986; Stead et al., Blood 71:742, 1988), mycophenolic acid (Stuhlmann et al., Proc. Natl. Acad. Sci. USA 81:7151, 1984), or various chemotherapeutic
5 agents (Guild et al., Proc. Natl. Acad. Sci. USA 85:1595, 1988; Kane et al., Gene 84:439, 1989; Choi et al., Proc. Natl. Acad. Sci. USA; Sorrentino, et al., Science 257:99, 1992). A discussion of selectable marker genes, including those capable of being amplified is provided in Kreigler,
10 1990, "Gene Transfer and Expression, A Laboratory Manual", Chapter 6, Stockton Press, and include the gene encoding dihydrofolate reductase.

Within another aspect, the present invention relates to a method of preparing recombinant erythropoietin
15 comprising transfecting a mammalian cell with an expression vector comprising a nucleic acid molecule encoding mammalian erythropoietin, an expression control sequence operatively linked thereto and at least one SAR element; culturing the transfected cell in a suitable
20 medium until sufficient amounts of erythropoietin are produced by the cell and separating the erythropoietin produced. In an embodiment, the mammalian cell may be further transfected with a selectable marker gene and the transfected cells may be selected by means of the
25 selectable marker gene. Examples of selectable marker genes are given above and include neo.

In an embodiment of the method, cells producing high levels of erythropoietin may be identified and selected and subcloned to establish long term cell lines from the
30 selected cells and; the selected cells may be cultured in a suitable medium until sufficient amounts of erythropoietin are produced by the cell. EPO produced may then be separated from the medium.

It is an advantage of the method of the invention
35 that cell lines may be established which are stable over the long term, at least over six months. The long term cell lines of the invention express consistently high

- 21 -

levels of EPO and may be maintained without the selective pressure often required to maintain the high copy number of amplified genes in cell lines which have been subjected to amplification.

5 EPO may be prepared by culturing the host/vector systems described above, in order to express the EPO. Recombinantly produced EPO may be further separated and further purified as described in more detail below.

Biologically active EPO expressed may be assayed by
10 known procedures such as tritiated thymidine uptake by mouse spleen cell erythrocyte precursors (Krystal, et al., 1986, Blood 67:71); the exhypoxic mouse method using ⁵⁹Fe incorporation into erythrocyte precursors (Cotes and Bangham, 1961, Nature 191:1065); ⁵⁹Fe uptake into fetal
15 mouse liver cells (Dunn et al, 1975, Exp. Hematol. 3:65); and the starved rat method (Goldwasser and Gross, 1975, Methods Enzymol. 37:109). EPO once expressed may also be quantitated, for example by RIA, separated and purified by known techniques such as ultrafiltration, flat-bed
20 electrofocusing, gel filtration, electrophoresis, isotachophoresis and various forms of chromatography, such as ion exchange, adsorption chromatography, column electrophoresis and various forms of HPLC. Procedures for the chromatographic separation of EPO are described, for
25 example in U.S. Patent No 4,667,016.

The present invention also relates to transgenic non-human mammals or embryos whose germ cells and somatic cells contain a DNA construct comprising the recombinant DNA molecule of the invention. The recombinant DNA
30 molecule of the invention may be expressed in non-human transgenic animals such as mice, rats, rabbits, sheep, cows and pigs (see Hammer et al. (Nature 315:680-683, 1985), Palmiter et al. (Science 222:809-814, 1983), Brinster et al. (Proc Natl. Acad. Sci USA 82:44384442,
35 1985), Palmiter and Brinster (Cell. 41:343-345, 1985) and U.S. Patent No. 4,736,866). Briefly, an expression unit, including a DNA sequence to be expressed together with

- 22 -

appropriately positioned expression control sequences, is introduced into pronuclei of fertilized eggs. Introduction of DNA is commonly done by microinjection. Integration of the injected DNA is detected by blot analysis of DNA from tissue samples, typically samples of tail tissue. It is preferred that the introduced DNA be incorporated into the germ line of the animal so that it is passed on to the animal's progeny. Tissue-specific expression may be achieved through the use of a tissue-specific promoter, or through the use of an inducible promoter, such as the metallothionein gene promoter (Palmiter et al., 1983, *ibid*), which allows regulated expression of the transgene. Alternatively, yeast artificial chromosomes (YACs) may be utilized to introduce DNA into embryo-derived stem cells by fusion with yeast spheroblasts carrying the YAC (see Capecchi, *Nature* 362:255-258, 1993; Jakobovits et al., *Nature* 362:255-258, 1993). Utilizing such methods, animals may be developed which express EPO in tissues. Tissue specific promoters may be used to target expression of EPO in cells. Tissue specific promoters include the 5' or 3' flanking sequences of the beta-globin, elastase, alpha-fetoprotein, alpha-A crystalline, an erythroid specific transcriptional element and insulin genes (Yee, et al. (1989) *P.N.A.S., U.S.A.* 86, 5873-5877; Swift, et al. 1984, *Cell* 38:639; Storb et al., *Nature (Lond.)* 310:238; Grosschedl et al., 1985 *Cell* 41:885; Shani, 1985 *Nature (Lond)* 314:238 and Chada et al, 1985, *Nature (Lond)*). The use of SAR elements in the development of transgenic animals is described for example in Xu, 1989, *J. Biol. Chem.* 264:21190; McKnight et al., 1992, *Proc. Natl. Acad. Sci. U.S.A.* 89:6943; Brooks, et al., 1994, *Mol. Cell. Biol.* 14:2243 and; Forrester, et al., 1994, *Science* 265:1221.

In a preferred embodiment suitable promoters and/or enhancers may be selected from mammary gland specific genes which are normally only expressed in milk, for example the genes encoding α -casein (Gene Pharming,

- 23 -

Leiden, Netherlands), β -casein (Genzyme Transgenics Corp. Framingham, Mass.), γ -casein, κ -casein α -lactalbumin β -lactalbumin β -lactoglobulin (PPL Therapeutics Ltd, Edinburgh, Scotland) and whey acidic protein (Altra Bio Inc., Arden Hills MN). Methods for targeting recombinant gene expression to the mammary gland of a mammal are described, for example, in U.S. Patent No. 5,304,489. Briefly, a DNA construct with the recombinant DNA molecule of the invention comprising a mammary gland specific promoter may be microinjected into a newly fertilized egg leading to integration of the construct into the genome and secretion of the protein into the milk of a mature lactating female. EPO expressed in the milk may be purified from the milk using standard procedures after skimming off the milk fat, separating out the caseins and precipitating EPO out of the whey fraction, followed by standard protein purification procedures for EPO as described elsewhere herein.

A major problem in the generation of transgenic mammals for the expression of recombinant proteins has been the varying levels of expression which result due to chromosomal factors in the local environment where the construct integrates, for example regulatory elements and the state of the chromatin (open or closed). As a result, generating a transgenic mammal that produces high levels of a recombinant protein has been achieved only by laborious trial and error.

The present invention provides a transgenic non-human animal whose germ cells and somatic cells contain a DNA construct comprising the recombinant DNA molecules of the invention, comprising a tissue specific promoter, preferably the tissue specific promoter is a promoter which specifically expresses EPO in milk. In a particularly preferred embodiment, the recombinant molecule contained in the transgenic non-human mammal comprises the nucleic acid molecule encoding EPO and the expression control sequence operatively linked thereto,

- 24 -

flanked by SAR elements. An advantage of DNA constructs having flanking SAR elements is that expression of EPO may be independent of the site of integration of the construct as the construct is insulated from surrounding chromosome material by the SAR elements, which define an open chromatin domain.

5. Applications

It will be apparent that the recombinant DNA molecules, expression vectors, transfected host cells, methods and transgenic animals of the invention will be useful for the efficient expression and production of recombinant mammalian EPO in vitro and in vivo as described above.

Recombinant EPO may be used to treat animals and human patients, including patients having anemia as a result of chronic renal failure. As EPO is the primary regulator of red blood cell formation, it has applications in both the diagnosis and treatment of disorders of red blood cell production and has potential applications for treating a range of conditions such as anemia, sickle cell disease, conditions where red cells are depleted (for example in bone marrow transplants), thalassemia, cystic fibrosis, menstrual disorders, acute blood loss and conditions involving abnormal erythropoiesis (for example cancers of the haemopoietic system), conditions involving destruction of red blood cells by over exposure to radiation, reduction in oxygen intake at high altitudes, complications or disorders secondary to AIDS and prolonged unconsciousness.

The recombinant DNA molecules, expression vectors and transformed mammalian cells of the invention will also have useful applications in gene therapy, whereby a functional EPO gene is introduced into a mammal in need thereof, for example mammals having anemias. The transfer of the recombinant DNA molecule of the invention into mammalian cells may be used, for example in gene therapy to correct an inherited or acquired disorder through the

- 25 -

synthesis of missing or defective EPO gene products in vivo.

The recombinant DNA molecule of the invention may be used in gene therapy as briefly described below. The
5 recombinant DNA molecule may be introduced into cells of a mammal, for example haemopoietic stem cells removed from the bone marrow or blood of the mammal. Hemopoietic stem cells are particularly suited to somatic gene therapy as regenerative bone marrow cells may be readily isolated,
10 modified by gene transfer and transplanted into an immunocompromised host to reconstitute the host's hemopoietic system. Suitable hemopoietic stem cells include primitive hemopoietic stem cells capable of initiating long term culture (Sutherland et al., Blood,
15 Vol. 74, p. 1563, 1986 and Udomsakdi et al., Exp. Hematol., Vol. 19, p. 338, 1991.) Suitable cells also include fibroblasts and hepatocytes.

The recombinant DNA molecules of the invention may be introduced into the cells by known methods, including
20 calcium phosphate mediated transfection described herein or retroviral mediated uptake. The recombinant DNA molecule of the invention may be directly introduced into cells or tissues in vivo using delivery vehicles such as retroviral vectors, adenoviral vectors and DNA virus
25 vectors. They may also be introduced into cells in vivo using physical techniques such as microinjection and electroporation or chemical methods such as coprecipitation and incorporation of DNA into liposomes. Recombinant molecules may also be delivered in the form of
30 an aerosol or by lavage. The recombinant DNA molecules of the invention may also be applied extracellularly such as by direct injection into cells. Freed et al., New Eng. J. Med. 327(22):1549-1555, 1992, describe a method for injecting fetal cells into brains of Parkinson's patients.
35 Gene therapy involving bone marrow transplant with recombinant primary hemopoietic stem cells requires efficient gene transfer into the stem cells. As a very

- 26 -

small number of primary stem cells can reconstitute the entire host hemopoietic system it is important that the transferred gene be efficiently expressed in the recombinant stem cells transferred. Thus it is expected
5 that the recombinant molecules of the invention will be particularly advantageous for use in gene therapy to correct defects in the erythropoietin gene.

As hereinbefore noted, the recombinant DNA molecules of the invention, having flanking SAR elements, are
10 particularly useful for the expression of EPO in transgenic mammals and therefore they are particularly useful in gene therapy as the SAR elements define an open chromatin domain and insulate the construct from the surrounding chromosome material, thereby, providing
15 position-independent expression.

The following non-limiting examples are illustrative of the present invention:

EXAMPLES

EXAMPLE 1

20 Synthesis of EPO cDNA Sequences

EPO Oligonucleotide synthesis

EPO oligonucleotides were synthesized with the Applied Biosystems Inc. 392 DNA/RNA Synthesizer at the 0.2 μ m scale (~500 μ g). Oligonucleotide 5' ends were
25 phosphorylated, except for the ones coinciding with the 5' ends of each of the four blocks. Oligonucleotides lacking 5' phosphorylation were purified using the Applied Biosystems Oligo Purification Cartridge (OPC). Oligonucleotides with 5' phosphorylation were purified
30 from acrylamide gels (according to the protocol described in Sambrook, Fritsch, and Maniatis, 1989. Molecular Cloning: A Laboratory Manual, 2nd Edition. Cold Spring Harbor Laboratory Press, pp. 11.23 - 11.30). C₁₈ Sep-Pak cartridges from Millipore were used to remove salts. All
35 oligos were resuspended in double distilled H₂O.

Oligonucleotides EPO1 (SEQ ID NO. 1), EPO2 (SEQ ID NO. 2), EPO3 (SEQ ID NO. 3), EPO4 (SEQ ID NO. 4), EPO5

- 27 -

(SEQ ID NO. 5), EPO6 (SEQ ID NO. 6), EPO7 (SEQ ID NO. 7), EPO8 (SEQ ID NO. 8), EPO9 (SEQ ID NO. 9), EPO10 (SEQ ID NO. 10), EPO11 (SEQ ID NO. 11), EPO12 (SEQ ID NO. 12), EPO13 (SEQ ID NO. 13), EPO13b (SEQ ID NO. 14), EPO14 (SEQ ID NO. 15), EPO15 (SEQ ID NO. 16), EPO1 α (SEQ ID NO. 17), EPO2 α (SEQ ID NO. 18), EPO3 α (SEQ ID NO. 19), EPO4 α (SEQ ID NO. 20), EPO5 α (SEQ ID NO. 21), EPO6 α (SEQ ID NO. 22), EPO7 α (SEQ ID NO. 23), EPO8 α (SEQ ID NO. 24), EPO9 α (SEQ ID NO. 25), EPO10 α (SEQ ID NO. 26), EPO11 α (SEQ ID NO. 27), EPO12 α (SEQ ID NO. 28), EPO13 α (SEQ ID NO. 29), EPO13B α (SEQ ID NO. 30), EPO14 α (SEQ ID NO. 31) and EPO15 α (SEQ ID NO. 32) as shown in Figure 1B were synthesized. All oligonucleotides labelled with " α " are for the complementary strand (i.e. negative sense of the EPO gene). Oligonucleotides EPO1 (SEQ ID NO. 1), EPO1 α (SEQ ID NO. 17), EPO15 (SEQ ID NO. 16) and EPO15 α (SEQ ID NO. 32) contain extra bases at their 5'-ends and 3'-ends, respectively, which facilitate construction of a HindIII recognition site.

20 Assembly of blocks 1, 2, 3 and 4

Blocks 1, 2, 3, and 4 as shown in Figure 1A were synthesized by ligating the above-noted EPO oligonucleotides according to the following protocol.

40 pmoles of each oligonucleotide were mixed in a microcentrifuge tube in a final volume of 50 μ l. The oligonucleotides were annealed by heating at 98°C for 5 minutes in a heat block. The heat block containing the tube was removed from the heating unit and allowed to cool on the benchtop to 30°C (approximately 1.5 hrs). 6 μ l of 10X T₄ DNA ligase buffer (0.5M Tris-HCl, pH 7.8, 0.1M MgCl₂, 0.1M DTT, 10mM ATP and 250 μ g/ml BSA), was added to 2 μ l (or 2 units) of T₄ DNA ligase, and brought to volume to 60 μ l with double distilled H₂O and incubated overnight at 14°C. The mixture was heated at 75°C for 10 minutes to inactivate ligase and then cooled on ice to dissociate non ligated oligonucleotides and ethanol precipitate.

Blocks 1, 2, 3 and 4 were purified as follows.

- 28 -

Each ligation mix was run on a 3% low melting agarose gel. No band of the expected size was visible on the gel. However, DNA was extracted from the region of the gel where the gene block was expected to be. The rationale was that there was a small amount of the correct gene block present.

The DNA extracted from the agarose gel was amplified by the polymerase chain reaction (with the NE Biolabs Vent DNA polymerase, 1 cycle 30 sec at 98°C, 25-30 cycles 30 sec at 98°C, 40 sec at 50-55°C and 2 min at 72°C, 1 cycle 10 min at 72°C, and cooled at 6°C. The primers were complementary to the ends of the gene blocks and contained a few extra bases so that the entire recognition sites for the specific restriction enzymes flanking each block would be present in each complete block. Blocks were then cloned into the SmaI site of pUC18 or pUC19 plasmids.

Assembled gene blocks were sequenced by the dideoxy-terminator method (Sanger, and Coulson, 1975, J. Mol. Biol. 94, 441-448). Typically, 5-12 clones had to be sequenced for each gene block in order to identify one with the expected sequence.

EPO cDNA sequences were assembled as described in Example 2 herein. EPO_{short} and EPO_{long} cDNA were assembled into pUC18 as shown in Figures 2A and 2B, to generate pLW20 and pLW21, respectively.

EXAMPLE 2

Assembly of Expression Vectors

Synthesis and assembly of EPO cDNA

Two EPO cDNA sequences were chemically synthesized: EPO_{short} and EPO_{long}. The reason for making both a long and a short version of the gene was based on previous results while expressing another gene in COS cells. It had been noted that reducing the length of the 3' non-coding sequence coincided with increased expression of the gene. However, this was not observed with EPO. Therefore the constructs used for this example contained the EPO_{long} cDNA,

- 29 -

as shown in SEQ ID NO. 35 and Figure 4.

Figure 1A, provides a schematic representation of the synthesis and assembly of the EPO_{long} cDNA sequence (SEQ ID NO. 35 and Figure 4) from the oligonucleotides. Briefly, the coding and complementary strands from contiguous oligonucleotides which had an average length of 60 bases were synthesized. The breakpoints between the oligonucleotides were chosen such that when two complementary oligonucleotides annealed, cohesive ends compatible with those of the adjoining oligonucleotide pair were created. The EPO_{long} cDNA (SEQ ID NO. 35 and Figure 4) was constructed from fifteen oligonucleotide pairs, shown in Figure 1B and SEQ ID NOS. 1-32) The coding strand oligonucleotides were numbered from 1 to 15 except for 13 which was replaced with 13b, and the complementary strand oligonucleotides were numbered 1α to 15α except for 13α which was replaced with 13bα.

The fifteen oligonucleotide pairs were assembled in four blocks. Each junction between adjacent blocks constitutes a unique restriction site. Only three silent mutations were introduced into the EPO_{long} cDNA sequence for the creation of unique restriction sites: (1) C at position 22 was replaced with A, to add a BstXI site, (2) C at position 256 was replaced with T, to remove a PstI site, and (3) C at position 705 was replaced with T, to add a SspI site. The assembly of the four blocks was done in PUC18, leading to the vector pLW21. pLW21 is the pUC18 vector with the 788 bp EPO_{long} cDNA sequence, as shown in SEQ ID NO. 35 and Figure 4, inserted in the HindIII restriction site.

Isolation of genomic EPO DNA

A human leukocyte genomic library was purchased from Clontech and was screened by plaque hybridization with fragments of EPO cDNA as probes. A 2.4kb (2,365bp) EPO genomic clone was isolated. This clone spans the HUMERPA sequence (Genbank, accession number M11319) (SEQ ID NO. 33 and Figure 3A) from nucleotide 499 to nucleotide 2365,

- 30 -

that is to say its 5' end maps 126 nucleotides upstream of the ATG initiation coding of the EPO pre-protein. The rationale for isolating the EPO gene was that the length of the DNA between the SAR elements would be longer and might allow for an increased effect of the SAR elements.

SAR elements

Two human apolipoprotein B (apoB) SAR elements were used which co-map with the boundaries of the human apolipoprotein B gene chromatin domain (Levy-Wilson & Fortier, 1989, J. Biol. Chem. 264:21196). The following clones were used: Rh10 carrying the distal 1212 bp-long 5' human apoB SAR element and 1317 bp of proximal sequence (SEQ ID NO. 37 and Figure 6) and a clone (Rh32) carrying the 605 bp long 3' hu apoB SAR element (SEQ ID NO. 36 and Figure 5).

The DNA sequence of Rh10 was determined by dideoxy-terminator method (Sanger, F. and Coulson, A.R., 1975, J. Mol. Biol. 94:441) and is shown in SEQ ID NO. 37 and Figure 6. The 2529 bp Rh10 sequence consists of the 1212 bp 5' distal human apoB SAR elements and the 1317 bp 5' proximal sequence in the 5' to 3' orientation. The DNA sequence of Rh32 was also determined, and was found to be identical to the sequence published in Levy-Wilson & Fortier (1989, J. Biol. Chem. 264:21196) (SEQ ID NO. 36 and Figure 5), except for a 60 base pair deletion spanning nucleotides 259 to 318, shown within brackets in Figure 5. Contrary to Rh10 which is not a typical SAR sequence, Rh32 is A/T rich and contains 22 copies of the ATATTT motif.

Regulatory Elements of Expression Vectors

Two basic expression vectors were derived from pAX111 and pAX142 (renamed pLW19 or pSB3 and pLW18 or pSB2, respectively). pAX111 (Kay & Humphries, Methods Mol. Cell. Biol. 2:254, 1991) carries the human cytomegalovirus IE enhancer and promoter and the β -globin intron, while pAX142 carries the elongation factor-1 α promoter and intron. For each of these vectors there are single restriction sites located on each site of the EPO

- 31 -

transcription unit, where the SAR elements were introduced (SpeI or EcoRV at the 5' end and HpaI at the 3' end). Maps of the two vectors pLW18 (pSB2) and pLW19 (pSB3) are shown in Figures 7 and 8 respectively.

5 Assembly of Expression Vectors

The EPO_{long} cDNA sequence (SEQ ID NO.35, Figure 4) or the genomic EPO DNA (SEQ ID NO. 33, Figure 3A) were introduced clockwise into the cloning sites of the expression vectors. In the case of the genomic clones, the β -globin and EF1 introns were removed from the pSB3 and pSB2 vectors, respectively. A summary of the expression vectors is shown in Table 1.

Construction of pLW24 and pLW25 Vectors

The EPO_{long} cDNA (SEQ ID NO.35, Figure 4) was removed from pLW21 by digestion with HindIII, was blunt-ended with the T4 DNA polymerase and was introduced in the clockwise orientation into the SmaI site of pLW18 and pLW19 to generate pLW24 and pLW25, respectively.

Construction of p24MAR1 and p25MAR1

Introduction of the 5' human apoB SAR element at the 5' end of the EPO transcription unit was accomplished as follows. The 2,529 bp XbaI fragment from Rh10 (SEQ ID NO. 37, Figure 6) was introduced in the clockwise orientation into the SpeI site of pLW24 and pLW25 to generate p5MAR24 and p5MAR25, respectively (Note that XbaI and SpeI sites are compatible).

Introduction of the 60 bp-deleted 3' human apoB SAR element at the 3' end of the EPO transcription unit was accomplished as follows. The 605 bp DraI-RsaI fragment from the plasmid 12 DI Eco was added XhoI linkers and cloned into the XhoI site of the Stratagene pSBII SK(+) plasmid, to generate plasmid 3'apoBX (Rh32) (SEQ ID NO. 36, Figure 5). The ~605 bp SAR fragment was then removed from Rh32 by XhoI digestion, blunt-ended with the Klenow enzyme and cloned into the HpaI site of p5MAR24 and p5MAR25 to generate p24MAR-1 and p25MAR-1, respectively. The orientation of the inserted fragments has not yet been

- 32 -

determined.

Construction of pAP142 and pAP140

Plasmids pSB2 and pSB3 were derived from pLW18 and pLW19, respectively. A 12bp DNA linker with the EcoRV and SphI restriction sites was inserted into the KpnI site of pLW18 and pLW19 to generate pSB2 and pSB3, respectively. This allowed for introduction of SAR elements into the blunt-end EcoRV restriction site, just upstream of the EPO transcription unit.

10 The EPO_{long} cDNA sequence was removed from pLW24 by digestion with Sall and cloned in the clockwise orientation into the Sall site of pSB2 to generate pAP13. pAP5 was generated by removing the EPO_{long} cDNA sequence from pLW25 by digestion with BamHI and cloning in the clockwise orientation into the BamHI site of pSB3 to generate pAP5.

The Rh32 ~605 bp XhoI SAR fragment (60 bp-deleted 3' human apoB SAR element) was blunt-ended with the T4 DNA polymerase and inserted in the clockwise orientation into the EcoRV site of pAP13 and pAP5 to generate pAP138 and pAP136, respectively. The same Rh32 ~605 bp XhoI blunt-ended SAR fragment was inserted in the clockwise orientation into the HpaI site of pAP138 and pAP136 to generate pAP142 and pAP140, respectively.

25 Construction of pAP59 and pAP67

pAP42 is an intronless version of pSB2. pSB2 was amplified by the polymerase chain reaction between nucleotides 1308 and 321, and the amplified fragment was ligated on itself to produce pAP42. pAP43 is an intronless version of pSB3. The SmaI - XmnI fragment (nucleotides 677 - 1320) was removed from pSB3 to produce pAP43.

35 The EPO genomic clone was isolated from a Clontech library (Cat. No. HL1006d; Lot No. 19412) by probing with the BamHI EPO_{short} cDNA fragment from pAP4. The EPO_{short} cDNA fragment used as a probe to isolate the genomic EPO clone was a BamHI fragment from pAP4. As for EPO_{long} cDNA, EPO_{short} cDNA was first assembled into the HindIII site of the

- 33 -

pUC18 vector, to generate the pLW20 vector, blunt-ended with the T4 DNA polymerase and inserted in the clockwise orientation into the SmaI site of pLW19 to generate pLW23. Then the EPO_{short} cDNA sequence was removed from pLW23 by
5 BamHI digestion and cloned in the clockwise orientation into the BamHI site of pSB3 to generate pAP4.

Plaque hybridization was performed according to the method described in "Molecular Cloning. A Laboratory Manual, 2nd Edition. 1989". Edited by Sambrook, Fritsch, and Maniatis, Cold Spring Harbor Laboratory Press. pp
10 2.108 - 2.121. A 7.5 kb BamHI fragment (cloned in the Stratagene pBS (KS+) plasmid) was identified as an EPO genomic clone. The identity of this clone was confirmed by polymerase chain reaction between primers EPOGEN 1
15 (nucleotides 499- 518 in HUMERPA sequence) and EPOGEN 12 (nucleotides 2848 - 2863, on complementary strand, in HUMERPA sequence). This resulted in the expected fragment. The 2,365 bp amplified fragment was cloned in the clockwise orientation into the HincII site of pUC19 to
20 generate pAP41. The EPO genomic sequence was then removed from pAP41 by EcoRI and HindIII digestion, blunt-ended with the T4 DNA polymerase and inserted in the clockwise orientation into the SmaI site of pAP42 to generate pAP59 or into the blunt-ended BamHI site of pAP43 to generate
25 pAP67.

Construction of pAP123, pAP127, pAP132 and pAP134

The Rh32 ~605 bp XhoI SAR fragment (60 bp-deleted 3' human apoB SAR element) was blunt-ended with the T4 DNA polymerase and inserted in the clockwise orientation into
30 the HpaI site of pAP59 and pAP67 to generate pAP117 and pAP119, respectively. The same Rh32 ~605 bp XhoI blunt-ended SAR fragment was inserted in the clockwise orientation into the EcoRV site of pAP117 and pAP119 to generate pAP123 and pAP127, respectively.

35 The 2,529 bp XbaI fragment from Rh10 was blunt-ended with the T4 DNA polymerase, and introduced in the clockwise orientation into the EcoRV site of pAP117 and

- 34 -

pAP119 to generate pAP132 and pAP134, respectively.

EXAMPLE 3

Transfection and Expression of EPO

Transfection

5 Briefly as described in more detail below CHO-K1 cells were co-transfected by the calcium phosphate precipitate method by two pairs of vectors: pSV2-neo carrying the resistance to the selective agent G-418 and one of the two following vectors expressing the EPO cDNA from the EF1 promoter: pLW24 or p24-MAR. pLW24 had no SAR
10 element, while p24-MAR had the 5'apo B SAR element (Rh10) upstream of the EF 1 promoter region and the 60 bp-deleted 3'apoB SAR element (Rh32) downstream of the EPO cDNA.

G-418 was added to the medium to select cells
15 transfected with pSV2-neo. At least 80% of these transfectants were expected to have been co-transfected with the EPO vector.

The following protocol was used for transfection with the Mammalian Transfection Kit by Stratagene (Catalog
20 #200285). On day -1 100mm culture dishes were inoculated with exponentially growing mammalian cells at a concentration of 5×10^4 cells per ml in 10 ml. The cells were grown overnight at 37°C with the appropriate level of CO₂ and in appropriate medium. For CHO-K1 cells Ham's F12
25 complete medium with 10% fetal calf serum (FCS) was used and incubation was carried out with 5% CO₂. The cells were approximately 10-20% confluent on day zero.

The optimal amount of DNA to be used for transfection varied depending on the cell type being used
30 for transfection. Usually, 10-30 µg of plasmid DNA was used. The plasmid used for selection was generally added at some ratio to the expression vector. For pSV2neo, a ratio of 1:10 to 1:15 was found to be appropriate.

The desired amount of DNA was diluted to 450 µl with
35 double distilled H₂O. 50 µl of solution 1 (2.5M Ca Cl₂, included in the Stratagene kit) was added slowly and

- 35 -

dropwise. 500 μ l of Solution 2 (2 x BBS, pH 6.95 [consists of 50 mM n, n-bis (2-hydroxyethyl)-2-aminoethanesulfonic acid and buffered saline, 280 mM NaCl and 1.5 mM Na_2HPO_4]) was added and mixed gently and slowly. It was found to be important to perform these two additions slowly and gently. The mixture was allowed to incubate at room temperature for 10-20 minutes. The precipitate was gently mixed to ensure adequate suspension. The precipitate was added to the culture dropwise while gently swirling the plate to distribute the suspension evenly, followed by incubation for 12-24 hours.

Where spare incubator space was available, it was determined that transfection efficiency could be improved 2-3 times by using lower CO_2 concentrations at this point (2-4% is recommended; 3% seemed to work well with CHO cells). Normal CO_2 concentrations were resumed after removal of precipitate on Day 1.

On day 1 the medium was removed by aspiration and the culture rinsed twice with sterile PBS (Phosphate buffered saline without Ca^{2+} , Mg^{2+}) or medium without serum. Fresh complete medium was applied (as on Day - 1) and the cells incubated under optimal CO_2 concentration for 24 hours.

The cells were split at a ratio ranging from 1:30 to 1:100 into 96 well plates (0.2 ml per well). For CHO-K1 cells, Ham's F12 complete medium with 20% FCS was used at this step. Incubation was carried out at 37°C with 5% CO_2 .

On day 4 the medium was aspirated and selective medium was added. For transfections using CHO-K1 cells and pSV2neo as the selective plasmid, Ham's F12 complete medium with 20% FCS + 270-400 $\mu\text{g/ml}$ G418 was used.

On day 5 or 6 (preferably day 5) and on day 8, the cultures were refed with selective medium.

On day 10, spent medium was collected for RIA assays and frozen. The spent medium was replaced with selective medium.

From day 11 RIA assays, were performed to determine

- 36 -

levels of EPO production in the medium, using undiluted samples. Samples producing high levels of EPO were cloned and subcultured in Ham's F12 complete medium with 10% FCS when they reached confluency.

5 EPO Production

Levels of EPO production in the medium were determined by RIA as follows.

The following materials and equipment were used in the assay: phosphate RIA buffer: 0.05M NaPO_4 ; 0.2% BSA; 10 0.02% NaN_3 , pH 7.4; Erythropoietin (standards, Boehringer Mannheim, Cat.# 1120166, 250 U/ml); ^{125}I -EPO (Amersham Cat.# IM.219); anti-rabbit IgG (whole molecule) developed in goat, whole antiserum (Sigma Cat.# R-5001 (abbrev. Ab2) polyethylene glycol 8000 (BDH Cat.#B80016); normal rabbit 15 serum (abbrev. NRS); Rabbit anti-EPO, polyclonal, 1mg (abbrev. Ab1) (R&D Systems Cat.# AB-286-NA) and; gamma counter (LKB-Wallac RIAGamma 1272).

The stock concentration of EPO was 250 U/ml. Eight standard concentrations were prepared from a stock 20 dilution of 20 U/ml sufficient for 4.5 ml of each standard or 20 assays in duplicate. $20 \text{ U/ml} = 88 \mu\text{l} @ 250 \text{ U/ml} + 1012 \mu\text{l}$ dilution buffer. The eight standard concentrations are shown in Table 2. The standards were divided into 450 μl aliquots in microcentrifuge tubes and 25 stored at -20°C until used.

Antibody 1 (1 mg) was dissolved in 1 ml RIA/DB and stored in 20 μl aliquots in 0.5 ml microcentrifuge tubes at -20°C until used (each aliquot was sufficient for 100 assay tubes). On the assay date, Ab1 was prepared at a 30 working concentration of $2 \mu\text{g/ml}$ with dilution buffer (a 1/500 dilution of the stock aliquot) to give a final assay concentration of $0.67 \mu\text{g/ml}$ in 300 μl when added as 100 μl to all tubes except non-specific binding (NSB) and total counts (TC).

35 Since all standard and sample binding inhibition % were based on the maximum binding (MB), to avoid the possibility of having a poor reference duplicate, the MB

- 37 -

was determined in quadruplicate.

The ^{125}I -EPO was diluted with 4.5 ml of dilution buffer and divided into 25 x 0.2 ml aliquots in 500 μl microcentrifuge tubes. A 5 μl sample was added to 50 μl of dilution buffer in an 11x75 mm tube and counted for 1 min. in the RIAGamma using program 2. The corrected CPM usually ranged between 4500 - 6000 CPM/ μl . The tracer aliquots were stored, with lead shielding, at -20°C until used.

Table 3 lists the assay setup and addition of reagents. The reagents were added and incubated in the following order: A) dilution buffer and NRS @ 1/33.3 were added to the appropriate tubes 3-8; B) EPO standards and sample dilutions were added to the appropriate tubes; C) antibody 1 was added to all tubes except 1-4 and; all tubes were vortexed and incubated at room temperature for 4h. ^{125}I -EPO @ 6000 CPM/100 μl was added to all tubes. As the tracer activity decreases over time, the maximum binding % decreases resulting in a loss of sensitivity and accuracy. Therefore, we used 6000 CPM total counts during the first week of a new batch and increased by 1000 CPM per week thereafter.

All tubes (except TC's) were vortexed and incubated overnight (18-20 hours) @ 4°C . Ab 2 and NRS (1/62.5) was added to all tubes except TC's. All tubes (except TC's) were vortexed and incubated at room temperature for 2 hours. 1.5ml of 3.8% PEG 8000 (w/v in dilution buffer) was added to all tubes (except TC's) resulting in a final PEG concentration of 3%. All tubes (except TC's) were vortexed and incubated for 10 minutes at room temperature. All tubes were centrifuged (except TC's) at $1500 \times g$ and 4°C for 20 minutes ($1500 \times g = 2800 \text{ RPM}$ when using the IEC Centra-8R with the Cat.# 5737 12x75 mm tube adapters). The supernants were removed by aspiration and the tubes containing the pellets were counted in the gamma counter.

The standard curve was plotted using linear regression of logit (B/B_0) vs log concentration where B = CPM bound and, B_0 = maximum CPM bound (reference binding

- 38 -

of Ab 1 without inhibitor). The regression line $y = C0 + C1(x)$ where, $C0 = y$ intercept, $C1 =$ slope, $x = \text{Log (Concentration)}$, $y = \text{Log (R/(1-R))}$ and, $R = B/B0$.

Interference of culture medium was tested by the
5 addition of up to 95 μl of a possible 100 μl sample volume of Ham's F-12 containing 10% FCS. No effect on binding was observed. Recovery of EPO at 100, 300, and 600 mU/ml was 93.85, 100.41, and 96.33% respectively.

Screening was performed as follows. The assay was
10 performed in one day for screening samples by using the following modifications to the above-noted method. Standards and sample dilutions were incubated with Ab1 for 1 hour at 37°C instead of 4 hours at room temperature. ^{125}I -EPO was incubated with all tubes for 1 hour at 37°C
15 instead of overnight at 4°C. Antibody 2 and NRS are incubated for 1 hour at 37°C instead of 2 hours at room temperature. The remaining procedures were as described above and the results are given below.

The first transfection series was performed with the
20 following target vectors: PLW24 (EF1 promoter, EPO_{long}) referred to as EPO-1 or; p24MAR-1 (EF1 promoter, EPO_{long} , 5'apoB & 3' 60 bp-deleted apoB SAR elements) referred to as EPO-1'. The selection plasmid was pSV2neo. The target:selection plasmid ratio was 5:1 (30 μg :6 μg).

25 One sample was picked up randomly from each transfection and was cloned by the dilution method. EPO-1-0-1 was cloned from the EPO-1 transfection and EPO-1-0-4' from the EPO-1' transfection (' indicates the presence of SAR elements in the target vector).

30 After the first round of cloning, the two EPO-1 clones and four EPO-1' clones expressing the highest levels of EPO were selected and expanded. Levels of EPO production in the medium, determined by the RIA assays were as follows: EPO-1-1-5: 8 u/10⁶ cells/day; EPO-1-1-6:
35 9 u/10⁶ cells/day; EPO-1-1-7': 41 u/10⁶ cells/day; EPO-1-1-8': 30 u/10⁶ cells/day; EPO-1-1-13': 125 u/10⁶ cells/day and; EPO-1-1-14': 81 u/10⁶ cells/day.

- 39 -

After a second round of cloning, levels of EPO expression were as follows: EPO-1-2-22: 5 u/10⁶ cells/day; EPO-1-2-23: 7 u/10⁶ cells/day; EPO-1-2-26: 13 u/10⁶ cells/day; EPO-1-2-27: 19 u/10⁶ cells/day; EPO-1-2-15*: 13 u/10⁶ cells/day; EPO-1-2-16*: 20 u/10⁶ cells/day and; EPO-1-2-17*: 105 u/10⁶ cells/day.

The second transfection series was performed with the same target and selection vectors as the first transfection series. The target plasmid:selection plasmid ratio was 12:1 (30µg:2.5µg).

At day 10 after transfection, EPO-2-0-11 (producing 0.8 u/ml EPO) from EPO-2 transfection (target plasmid has no SAR elements) and EPO 2-0-9* (producing 0.6 u/ml) from EPO-2* transfection (target plasmid with SAR elements) were selected for cloning. 21 days after cloning, the levels of EPO production in the medium for EPO-2-0-11 were as follows: 36/48 samples had <160 u/ml; 11/48 samples had 160-800 u/ml; and 1/48 samples had 800 u/ml. Levels of EPO production for EPO-2-0-9* were as follows: 47/48 samples had 1,000-4,000 u/ml and; 1/48 samples had <800 u/ml.

Two of the EPO-2 clones and three of the EPO-2* clones (expressing the highest levels of EPO per cell cluster) were expanded, and the levels of expression were as follows: EPO-2-1-24 (514 u/ml 21 days after cloning) and 109 u/10⁶ cells/day after expansion; EPO-2-1-25 (800 u/ml 21 days after cloning) and 182 u/10⁶ cells/day after expansion; EPO-2-1-18* (1,962 u/ml 21 days after cloning) and 185 u/10⁶ cells/day after expansion; EPO-2-1-19* (1,682 u/ml 21 days after cloning) and 1,306 u/10⁶ cells/day after expansion and; EPO-2-1-21* (1,777 u/ml 21 days after cloning) and 332 u/10⁶ cells/day after expansion.

EPO-2-1-19* was found to maintain its levels of EPO production while submitted to successive freezing-revival cycles as follows: 962 and 1,038 u/10⁶ cells/day after the first cycle; 1,323 and 1,264 u/10⁶ cells/day (between days 3 and 4) after the second cycle and; 1,188 u/10⁶ cells/day

- 40 -

(between days 3 and 4) after the third cycle.

EPO-2-1-19* was submitted to a second round of cloning. The clones producing the highest levels of EPO produced between 1,500 and 1,700 u/10⁶ cells/day (between
5 days 3 and 4). The EPO-2-1-19* cell line has remained stable and expressed constant levels of EPO for about eight months.

TABLE 1**Assembly of expression vectors**

EF1 promoter	CMV promoter	EPO sequence	5' SAR element	3' SAR element
pLW24 Rh49	pLW25 Rh216	cDNA _{long}	-	-
p24MAR-1 Rh163	p25MAR-1 Rh169	cDNA _{long}	Rh10	Rh32
pAP142 Rh223	pAP140 Rh233	cDNA _{long}	Rh32	Rh32
pAP59 Rh183	pAP67 Rh209	genomic	-	-
pAP123 Rh211	pAP127 Rh206	genomic	Rh32	Rh32
pAP132 Rh221	pAP134 Rh222	genomic	Rh10	Rh32

SUBSTITUTE SHEET

TABLE 2

Standard No.	20 U/ml Stock (μl)	Dilution Buffer (μl)	Standard Concentration (mU/ml)
1	4.5	4495.5	20
2	9.0	4491.0	40
3	18.0	4482.0	80
4	36.0	4464.0	160
5	67.5	4432.5	300
6	135.0	4365.0	600
7	270.0	4230.0	1,200
8	450.0	4050.0	2,000

SUBSTITUTE SHEET

TABLE 3

Tube #	Code	Dilution Buffer (μl)	NRS @ 1/33.3 (μl)	EPO Standard (μl)	Ab 1 @ 2μg/ml (μl)	¹²⁵ I-EPO 6000 CPM (μl)	Ab 2 @ 1/5 (μl)	NRS @ 1/62.5 (μl)
1-2	TC	0	0	0	0	100	0	0
3-4	NSB	100	100	0	0	100	50	50
5-8	MB	100	0	0	100	100	50	50
Standard Curve								
9-10	20 mU/ml	0	0	100	100	100	50	50
11-12	40 mU/ml	0	0	100	100	100	50	50
13-14	80 mU/ml	0	0	100	100	100	50	50
15-16	160 mU/ml	0	0	100	100	100	50	50
17-18	300 mU/ml	0	0	100	100	100	50	50
19-20	600 mU/ml	0	0	100	100	100	50	50
21-22	1200 mU/ml	0	0	100	100	100	50	50
23-24	2000 mU/ml	0	0	100	100	100	50	50
Inter/Intra-assay Quality Controls								
25-26	100 mU/ml	0	0	100	100	100	50	50
27-28	400 mU/ml	0	0	100	100	100	50	50
29-30	800 mU/ml	0	0	100	100	100	50	50
Unknowns								
31-32	Sample 1	100 μl of Sample Dilution	0	0	100	100	50	50

SUBSTITUTE SHEET

- 44 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANTS:

(A) NAME: Cangene Corporation
(B) STREET: 104 Chancellor Matheson Road
(C) CITY: Winnipeg
(D) STATE: Manitoba
(E) COUNTRY: Canada
(F) POSTAL CODE: R3T 2N2
(G) TELEPHONE NO.: (204) 989-6850
(H) TELEFAX NO.: (204) 269-7003

(A) NAME: Delcuve, Geneviève
(B) STREET: 74 McGill Place
(C) CITY: Winnipeg
(D) STATE: Manitoba
(E) COUNTRY: Canada
(F) POSTAL CODE: R3T 5B2

(ii) TITLE OF INVENTION: Recombinant DNA Molecules and Expression Vectors for Erythropoietin

(iii) NUMBER OF SEQUENCES: 37

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: BERESKIN & PARR
(B) STREET: 40 King Street West
(C) CITY: Toronto
(D) STATE: Ontario
(E) COUNTRY: Canada
(F) ZIP: M5H 3Y2

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: McDiarmid, Shona S.
(B) REGISTRATION NUMBER: 38,798
(C) REFERENCE/DOCKET NUMBER: 7841-013

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (416) 364-7311
(B) TELEFAX: (416) 361-1398

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 51 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- 45 -

(A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:

(B) CLONE: EPO1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

AGCTTGCCCG GGATGAGGGC CACCGGTGTG GTCACCCGGC GCGCCCCAGG T

51

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 44 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:

(B) CLONE: EPO2

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

CGCTGAGGGA CCCCGGCCAG GCGCGGAGAT GGGGGTGAC GAAT

44

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 51 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:

(B) CLONE: EPO3

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GTCCTGCCTG GCTGTGGCTT CTCCTGTCCC TGCTGTCGCT CCCTCTGGGC C

51

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 59 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:

- 46 -

(B) CLONE: EPO4

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

TCCCAGTCCT GGGCGCCCCA CCACGCCTCA TCTGTGACAG CCGAGTCCTG GAGAGGTAC 59

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 56 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: EPO5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CTCTTGAGG CCAAGGAGGC CGAGAATATC ACGACGGGCT GTGCTGAACA TTGCAG 56

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 58 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: EPO6

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

CTTGAATGAG AATATCACTG TCCCAGACAC CAAAGTTAAT TTCTATGCCT GGAAGAGG 58

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 55 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: EPO7

- 47 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

ATGGAGGTCG GGCAGCAGGC CGTAGAAGTC TGGCAGGGCC TGGCCCTGCT GTCGG 55

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 61 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: EPO8

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

AAGCTGTCCT GCGGGGCCAG GCCCTGTTGG TCAACTCTTC CCAGCCGTGG GAGCCCCTGC 60
A 61

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 54 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: EPO9

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

GCTGCATGTG GATAAGCCG TCAGTGGCCT TCGCAGCCTC ACCACTCTGC TTCG 54

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 51 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: EPO10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

- 48 -

GGCTCTGGGA GCCCAGAAGG AAGCCATCTC CCCTCCAGAT GCGGCCTCAG C

51

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 51 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:

(B) CLONE: EP011

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

TGCTCCACTC CGAACAATCA CTGCTGACAC TTTCCGCAAA CTCTTCCGAG T

51

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 47 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:

(B) CLONE: EP012

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

CTACTCCAAT TTCCTCCGGG GAAAGCTGAA GCTGTACACA GGGGAGG

47

(2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 48 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:

(B) CLONE: EP013

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

CCTGCAGGAC AGGGGACAGA TGACCAGGTG TGTCGACCTG GGCATATC

48

(2) INFORMATION FOR SEQ ID NO:14:

- 49 -

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 48 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: EP013b

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

CCTGCAGGAC AGGGGACAGA TGACCAGGTG TGTCCACCTG GGCATATC

48

(2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 50 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: EP015

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

CACCACCTCC CTCACCAATA TTGCTTGTGC CACACCCTCC CCCGCCACTC

50

(2) INFORMATION FOR SEQ ID NO:16:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 52 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: EP015

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

CTGAACCCCG TCGAGGGGCT CTCAGCTCAG CGCCAGCCTG TCCCATGGAC CA

52

(2) INFORMATION FOR SEQ ID NO:17:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 55 base pairs
 - (B) TYPE: nucleic acid

- 50 -

- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: EPO1 alpha

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

CCTCAGCGAC CTGGGGCGCG CCGGGTGACC ACACCGGTGG CCCTCATCCC GGGCA

55

(2) INFORMATION FOR SEQ ID NO:18:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 44 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: EPO2 alpha

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

GGCAGGACAT TCGTGCACCC CCATCTCCGC GCCTGGCCGG GGTC

44

(2) INFORMATION FOR SEQ ID NO:19:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 52 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: EPO3 alpha

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

GGACTGGGAG GCCCAGAGGG AGCGACAGCA GGGACAGGAG AAGCCACAGC CA

52

(2) INFORMATION FOR SEQ ID NO:20:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 46 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- 51 -

- (ii) MOLECULE TYPE: cDNA
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: EPO4 alpha

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

CTCTCCAGGA CTCGGCTGTC ACAGATGAGG CGTGGTGGGG CGCCCA

46

(2) INFORMATION FOR SEQ ID NO:21:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 52 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: EPO5 alpha

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

TTCAGCACAG CCCGTCGTA TATTCTCGGC CTCCTTGGCC TCCAAGAGGT AC

52

(2) INFORMATION FOR SEQ ID NO:22:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 58 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: EPO6A

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

AGGCATAGAA ATTAACCTTG GTGTCTGGGA CAGTGATATT CTCATTCAAG CTGCAATG

58

(2) INFORMATION FOR SEQ ID NO:23:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 55 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (vi) ORIGINAL SOURCE:

- 52 -

(A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:

(B) CLONE: EPO7 alpha

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

AGGGCCAGGC CCTGCCAGAC TTCTACGGCC TGCTGCCCCGA CCTCCATCCT CTTC 55

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 65 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:

(B) CLONE: EPO8 alpha

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

GGGGCTCCCA CGGCTGGGAA GAGTTGACCA ACAGGGCCTG GCCCCGCAGG ACAGCTTCCG 60
ACAGC 65

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 50 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:

(B) CLONE: EPO9 alpha

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

AGTGGTGAGG CTGCGAAGGC CACTGACGGC TTTATCCACA TGCAGCTGCA 50

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 51 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

- 53 -

- (vii) IMMEDIATE SOURCE:
(B) CLONE: EPO10 alpha

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

CGCATCTGGA GGGGAGATGG CTTCTTCTG GGCTCCCAGA GCGCGAAGCA G

51

- (2) INFORMATION FOR SEQ ID NO:27:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 61 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA

- (vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

- (vii) IMMEDIATE SOURCE:
(B) CLONE: EPO11 alpha

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

AGACTCGGAA GAGTTTGCGG AAAGTGTCAG CAGTGATTGT TCGGAGTGGA GCAGCTGAGG

60

C

61

- (2) INFORMATION FOR SEQ ID NO:28:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 53 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA

- (vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

- (vii) IMMEDIATE SOURCE:
(B) CLONE: EPO 12 alpha

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

CCTGCAGGCC TCCCCTGTGT ACAGCTTCAG CTTTCCCCGG AGGAAATTGG AGT

53

- (2) INFORMATION FOR SEQ ID NO:29:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 47 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA

- (vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

- (vii) IMMEDIATE SOURCE:

- 54 -

(B) CLONE: EPO13 alpha

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

GGTGGTGGAT ATGCCCAGGT CGACACACCT GGTCATCTGT CCCCTGT

47

(2) INFORMATION FOR SEQ ID NO:30:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 47 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:

(B) CLONE: EPO13b alpha

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

GGTGGTGGAT ATGCCCAGGT GGACACACCT GGTCATCTGT CCCCTGT

47

(2) INFORMATION FOR SEQ ID NO:31:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 51 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:

(B) CLONE: EPO14 alpha

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

GGGTCAGGA GTGGCGGGGG AGGGTGTGGC ACAAGCAATA TTGGTGAGGG A

51

(2) INFORMATION FOR SEQ ID NO:32:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 48 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:

(B) CLONE: EPO15 alpha

- 55 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

AGCTTGGTCC ATGGGACAGG CTGGCGCTGA GCTGAGAGCC CCTCGACG

48

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 3602 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: join(625..637, 1201..1346, 1605..1691,
2303..2482,
2617..2772).

(ix) FEATURE:

(A) NAME/KEY: mRNA

(B) LOCATION: join(625..637, 1201..1346, 1605..1691,
2303..2482,
2617..2772)

(ix) FEATURE:

(A) NAME/KEY: mat_peptide

(B) LOCATION: join(1269..1346, 1605..1691, 2303..2482, 2617
..2769)

(ix) FEATURE:

(A) NAME/KEY: prim_transcript

(B) LOCATION: join(625..3337)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

```

AAGCTTCTGG GCTTCCAGAC CCAGCTACTT TGC GGAACTC AGCAACCCAG GCATCTCTGA 60
GTCTCCGCCC AAGACCGGGA TGCCCCCAG GGGAGGTGTC CGGGAGCCCA GCCTTTCCCA 120
GATAGCACGC TCCGCCAGTC CCAAGGGTGC GCAACCGGCT GCACTCCCCT CCCGCGACCC 180
AGGGCCCCGG AGCAGCCCC ATGACCCACA CGCACGTCTG CAGCAGCCCC GCTCAGCCCC 240
CGGCGAGCCT CAACCCAGGC GTCCTGCCCC TGCTCTGACC CCGGGTGGCC CCTACCCCTG 300
GCGACCCCTC ACGCACACAG CCTCTCCCC ACCCCCACCC GCGCACGCAC ACATGCAGAT 360
AACAGCCCCG ACCCCCGGCC AGAGCCGCAG AGTCCCTGGG CCACCCCGGC CGCTCGCTGC 420
GCTGCGCCGC ACCGCGCTGT CCTCCCGGAG CCGGACCGGG GCCACCGCGC CCGCTCTGCT 480
CCGACACCGC GCCCCCTGGA CAGCCGCCCT CTCCTCTAGG CCCGTGGGGC TGGCCCTGCA 540
CCGCCGAGCT TCCCGGGATG AGGGCCCCCG GTGTGGTCAC CCGGCGCGCC CCAGGTCGCT 600
GAGGGACCCC GGCCAGGCGC GGAG ATG GGG GTG CAC G GTGAGTACTC 647
                               Met Gly Val His
                               -27   -25
GCGGGCTGGG CGTCCC GCCCGGGTCC CTGTTGAGC GGGGATTAG CGCCCCGGCT 707

```

- 56 -

ATTGGCCAGG AGGTGGCTGG GTTCAAGGAC CGGCGACTTG TCAAGGACCC CGGAAGGGGG 767
 AGGGGGGTGG GGCAGCCTCC ACGTGCCAGC GGGGACTTGG GGGAGTCCTT GGGGATGGCA 827
 AAAACCTGAC CTGTGAAGGG GACACAGTTT GGGGGTTGAG GGAAGAAGG TTTGGGGGTT 887
 CTGCTGTGCC AGTGGAGAGG AAGCTGATAA GCTGATAACC TGGGCGCTGG AGCCACCACT 947
 TATCTGCCAG AGGGGAAGCC TCTGTCACAC CAGGATTGAA GTTTGGCCCG AGAAGTGGAT 1007
 GCTGGTAGCT GGGGGTGGGG TGTGCACACG GCAGCAGGAT TGAATGAAGG CCAGGGAGGC 1067
 AGCACCTGAG TGCTTGCATG GTTGGGGACA GGAAGGACGA GCTGGGGCAG AGACGTGGGG 1127
 ATGAAGGAAG CTGTCCTTCC ACAGCCACCC TTCTCCCTCC CCGCCTGACT CTCAGCCTGG 1187
 CTATCTGTTT TAG AA TGT CCT GCC TGG CTG TGG CTT CTC CTG TCC CTG 1235
 Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu
 -22 -20 -15
 CTG TCG CTC CCT CTG GGC CTC CCA GTC CTG GGC GCC CCA CCA CGC CTC 1283
 Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu
 -10 -5 1 5
 ATC TGT GAC AGC CGA GTC CTG GAG AGG TAC CTC TTG GAG GCC AAG GAG 1331
 Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu
 10 15 20
 GCC GAG AAT ATC ACG GTGAGACCCC TTCCCCAGCA CATTCCACAG AACTCACGCT 1386
 Ala Glu Asn Ile Thr
 25
 CAGGGCTTCA GGGAACTCCT CCCAGATCCA GGAACCTGGC ACTTGGTTTG GGGTGGAGTT 1446
 GGGAAAGCTAG AACTTGCCCC CCTACATAAG AATAAGTCTG GTGGCCCCAA ACCATACCTG 1506
 GAAACTAGGC AAGGAGCAAA GCCAGCAGAT CCTACGGCCT GTGGGCCAGG GCCAGAGCCT 1566
 TCAGGGACCC TTGACTCCCC GGGCTGTGTG CATTTCAG ACG GGC TGT GCT GAA 1619
 Thr Gly Cys Ala Glu
 30
 CAC TGC AGC TTG AAT GAG AAT ATC ACT GTC CCA GAC ACC AAA GTT AAT 1667
 His Cys Ser Leu Asn Glu Asn Ile Thr Val Pro Asp Thr Lys Val Asn
 35 40 45
 TTC TAT GCC TGG AAG AGG ATG GAG GTGAGTTCCT TTTTTCCTTC 1721
 Phe Tyr Ala Trp Lys Arg Met Glu
 50 55
 TTTTGGAGAA TCTCATTTGC GAGCCTGATT TTGGATGAAA GGGAGAATGA TCGGGGAAA 1781
 GGTAAATGG AGCAGCAGAG ATGAGGCTGC CTGGGCGCAG AGGCTCACGT CTATAATCCC 1841
 AGGCTGAGAT GGCCGAGATG GGAGAATTGC TTGAGCCCTG GAGTTTCAGA CCAACCTAGG 1901
 CAGCATAGTG AGATCCCCCA TCTCTACAAA CATTTAAAAA AATTAGTCAG GTGAAGTGGT 1961
 GCATGGTGGT AGTCCAGAT ATTTGGAAGG CTGAGGCGGG AGGATCGCTT GAGCCCAGGA 2021
 ATTTGAGGCT GCAGTGAGCT GTGATCACAC CACTGCACTC CAGCCTCAGT GACAGAGTGA 2081
 GGCCCTGTCT CAAAAAGAA AAGAAAAAG AAAAATAATG AGGGCTGTAT GGAATACATT 2141
 CATTATTCAT TCACTCACTC ACTCACTCAT TCATTCATTC ATTCATTCAA CAAGTCTTAT 2201

- 57 -

TGCATACCTT CTGTTTGCTC AGCTTGGTGC TTGGGGCTGC TGAGGGGCAG GAGGGAGAGG 2261
 GTGACATGGG TCAGCTGACT CCCAGAGTCC ACTCCCTGTA G GTC GGG CAG CAG 2314
 Val Gly Gln Gln
 GCC GTA GAA GTC TGG CAG GGC CTG GCC CTG CTG TCG GAA GCT GTC CTG 2362
 Ala Val Glu Val Trp Gln Gly Leu Ala Leu Leu Ser Glu Ala Val Leu
 60 65 70 75
 CGG GGC CAG GCC CTG TTG GTC AAC TCT TCC CAG CCG TGG GAG CCC CTG 2410
 Arg Gly Gln Ala Leu Leu Val Asn Ser Ser Gln Pro Trp Glu Pro Leu
 80 85 90
 CAG CTG CAT GTG GAT AAA GCC GTC AGT GGC CTT CGC AGC CTC ACC ACT 2458
 Gln Leu His Val Asp Lys Ala Val Ser Gly Leu Arg Ser Leu Thr Thr
 95 100 105
 CTG CTT CGG GCT CTG GGA GCC CAG GTGAGTAGGA GCGGACACTT CTGCTTGCCC 2512
 Leu Leu Arg Ala Leu Gly Ala Gln
 110 115
 TTTCTGTAAG AAGGGGAGAA GGGTCTTGCT AAGGAGTACA GGAAGTGTCC GTATTCCTTC 2572
 CCTTTCTGTG GCACTGCAGC GACCTCCTGT TTTCTCCTTG GCAG AAG GAA GCC ATC 2628
 Lys Glu Ala Ile
 TCC CCT CCA GAT GCG GCC TCA GCT GCT CCA CTC CGA ACA ATC ACT GCT 2676
 Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile Thr Ala
 120 125 130 135
 GAC ACT TTC CGC AAA CTC TTC CGA GTC TAC TCC AAT TTC CTC CGG GGA 2724
 Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu Arg Gly
 140 145 150
 AAG CTG AAG CTG TAC ACA GGG GAG GCC TGC AGG ACA GGG GAC AGA TGACCAGGTG 2779
 Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp Arg
 155 160 165
 TGCCACCTG GGCATATCCA CCACCTCCCT CACCAACATT GCTTGTGCCA CACCCTCCCC 2839
 CGCCACTCCT GAACCCCGTC GAGGGGCTCT CAGCTCAGCG CCAGCCTGTC CCATGGACAC 2899
 TCCAGTGCCA GCAATGACAT CTCAGGGGCC AGAGGAACTG TCCAGAGAGC AACTCTGAGA 2959
 TCTAAGGATG TCACAGGGCC AACTTGAGGG CCCAGAGCAG GAAGCATTCA GAGAGCAGCT 3019
 TTAAACTCAG GGACAGAGCC ATGCTGGGAA GACGCCTGAG CTCACTCGGC ACCCTGCAAA 3079
 ATTTGATGCC AGGACACGCT TTGGAGGCGA TTTACCTGTT TTCGCACCTA CCATCAGGGA 3139
 CAGGATGACC TGGAGAACTT AGGTGGCAAG CTGTGACTTC TCCAGGTCTC ACGGGCATGG 3199
 GCACTCCCTT GGTGGCAAGA GCCCCCTTGA CACCGGGGTG GTGGGAACCA TGAAGACAGG 3259
 ATGGGGGCTG GCCTCTGGCT CTCATGGGGT CCAAGTTTTG TGTATTCTTC AACCTCATTG 3319
 ACAAGAACTG AAACCACCAA TATGACTCTT GGCTTTTCTG TTTTCTGGGA ACCTCCAAAT 3379
 CCCCTGGCTC TGTCCCACTC CTGGCAGCAG TGCAGCAGGT CCAGGTCCGG GAAATGAGGG 3439
 GTGGAGGGGG CTGGGCCCTA CGTGCTGTCT CACACAGCCT GTCTGACCTC TCGACCTACC 3499

- 58 -

GGCCTAGGCC ACAAGCTCTG CCTACGCTGG TCAATAAGGT GTCTCCATTC AAGGCCTCAC 3559
 CGCAGTAAGG CAGCTGCCAA CCCTGCCCAG GGCAAGGCTG CAG 3602

(2) INFORMATION FOR SEQ ID NO:34:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 193 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Ser Leu
 -27 -25 -20 -15
 Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu
 -10 -5 1 5
 Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu
 10 15 20
 Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu
 25 30 35
 Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg
 40 45 50
 Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu
 55 60 65
 Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser
 70 75 80 85
 Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly
 90 95 100
 Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu
 105 110 115
 Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile
 120 125 130
 Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu
 135 140 145
 Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp
 150 155 160 165
 Arg

(2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 788 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- 59 -

(A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:

(B) CLONE: EP0long

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

```

AGCTTGCCCG GGATGAGGGC CACCGGTGTG GTCACCCGGC GCGCCCCAGG TCGCTGAGGG  60
ACCCCGGCCA GCGCGGGAGA TGGGGGTGCA CGAATGTCCT GCCTGGCTGT GGCTTCTCCT 120
GTCCCTGCTG TCGCTCCCTC TGGGCCTCCC AGTCCTGGGC GCCCCACCAC GCCTCATCTG 180
TGACAGCCGA GTCCTGGAGA GGTACCTCTT GGAGGCCAAG GAGGCCGAGA ATATCACCAC 240
GGGCTGTGCT GAACATTGCA GCTTGAATGA GAATATCACT GTCCCAGACA CCAAAGTTAA 300
TTTCTATGCC TGGAAGAGGA TGGAGGTCGG GCAGCAGGCC GTAGAAGTCT GGCAGGGCCT 360
GGCCCTGCTG TCGGAAGCTG TCCTGCGGGG CCAGGCCCTG TTGGTCAACT CTTCCCAGCC 420
GTGGGAGCCC CTGCAGCTGC ATGTGGATAA AGCCGTCAGT GGCCTTCGCA GCCTCACCAC 480
TCTGCTTCGG GCTCTGGGAG CCCAGAAGGA AGCCATCTCC CCTCCAGATG CGGCCTCAGC 540
TGCTCCACTC CGAACAATCA CTGCTGACAC TTTCCGCAA CTCTTCCGAG TCTACTCCAA 600
TTTCCTCCGG GGAAAGCTGA AGCTGTACAC AGGGGAGGCC TGCAGGACAG GGGACAGATG 660
ACCAGGTGTG TCCACCTGGG CATATCCACC ACCTCCCTCA CCAATATTGC TTGTGCCACA 720
CCCTCCCCCG CCACTCCTGA ACCCCGTCGA GGGGCTCTCA GCTCAGCGCC AGCCTGTCCC 780
ATGGACCA

```

788

(2) INFORMATION FOR SEQ ID NO:36:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 605 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:

(B) CLONE: Rh 32

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

```

AAAAAGATGA GGTAATTGTG TTTTATAAT TAAATATTTT ATAATTAAAA TATTTATAAT  60
TAAAATATTT ATAATTAAAT ATTTTATAAT TAAAATATTT ATAATTAAAT ATTTTATAAT 120
TAAAATATTT ATAATTAAAT ATTTTATAAT TAAAATATTT ATAATTAAAT ATTTTATAAT 180
TAAAATATTT ATAATTAAAT ATTTTATAAT TAAAATATTT ATAATTAAAT ATTTTATAAT 240
TAAAATATTT ATAATTAAAT ATTTTATAAT TAAAATGTTT ATAATTACAT ATTTTATAAT 300
TAAAATGTTT ATAATTACAT ATTTTATAAT TAAAATGTTT ATAATTACAT ATTTTATAAT 360

```

- 60 -

TAAAATGTTT ATAATTACAT ATTTTATAAT TACATATTTT ATAAAGTATT TATAATTACA 420
TATTTTATAA TTAAAGTATT TATAATTACA TATTTTATAA TTAAAGTATT TATAATTACA 480
TATTTTATAA TTCAATATTT TATAAATAGT TAAAAAGACG AGGAAAAAAT TAAAAAGACG 540
AGGTTATTGA TCTCAGGAAT TGTATTTGCC AAGTGAGAAG GAAAAAATAT TCACAAAGGC 600
TTGTA 605

(2) INFORMATION FOR SEQ ID NO:37:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2529 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:
(B) CLONE: Rh 10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

TCTAGACCCC AGTTTCTCTA TAAGATGAGA ATATTAGTCA CGATTTGGTT TCTAAGATCC 60
TGTCTATGTT TGAGACTACA GATACCTGTT GCTACATTTT CCTTCATAGC TCTGAACAAG 120
GAGAATTCAG CCCAATTCTC ATGGCCTTCT AAACAATCCA GAGTTTCAGT GCCATAAGGT 180
ACTACAATTT AGTGTCAAAT TAAGTCAAAG GCTTCATTAG CCTGAAAGCT CTGTCCCTGG 240
CCTGGGCATG GCAAACGTGA TCCCCCACTG ACCATCCCCC TGTCTCCCTT CTCCCCAGAG 300
ACTCCAGTAG CCTGGCGTCA TCACAGGGGC CAGACATATC CAACATGTTT CCAGCTTCCT 360
GCCACTTGAC TTTCAGTGTG CCTCCCTCTT CAGTTACCCA AATCCTGCCC ACCATTCCAG 420
AGCCAGTTCA ATCTACCCA TCCAGGACCC CCGAGACCCC CATCGTACCA CTATAGTCTA 480
ACTGTGGTGT AGACCCCACTA CTGGGCACAT TGCCTACGCT CATTATTGGC TGTGACGTCT 540
GATTATGCCC TTCTCCTGGT CTGGAAGCTC TCGGAGGTGC TCCATAATAC ATGAAGAGAA 600
GTAGTGCTGG TGTGGGAATA GTGAGGTGTG TTTATCCATC CAGCTATCCG GCACCAGCAC 660
TGGTCTCAGC TTTCTGAGGT AACACGTTCT GAGCCTTAGT CTTGAGAGAA CATAAAGAAA 720
ACTTTTTTTA AAAGTAGTAA AAAGTGGCTG ACAAAGCTG ACCAAAAGCC TTCAAAGAAA 780
ATGCTAAGTT ATATCTAAGA AAGTTTACCC AAGGTCAGGC AAATATGAAA CCTAAAGCTA 840
GACGTGGGGA AGAAGTTCCG GAGAGTTGCA ATTCCCTGTG CCCCAGCATC CCCAGGAGGG 900
CATGCCCCACA TCTGATTTAG AAATCTGTGT AAAATGAGTG AAGGTTTCTA TTTCTTGGGC 960
AGTGTGGGCA CAGGTCTTTG GAGAGGTGCA TGGCCTCCCA TAAATCCTT CCTGCTTGAT 1020
GGTTCTGGAT CCTCAGCCAC AGCTCCTAAT AGCCATGAGG TTTGAGCCCA AAATAATTTA 1080
TGTGTTTGTT TTTTCAGCCC CAAAATTTCC ATAGAATCAA AGTAGTCAGA GCTGAATGGG 1140

- 61 -

GCTAAGAGAC CGTCCATTCC TGTCTTCTCA TCACAGATGA GGGACTGCCA CCCAGAGCCG 1200
TAGAAACTGT CCCATGGCCC CAGTTCCCAG ACCCTTCCTC TCTCCTACAG CTCCAAGTTC 1260
ACTGTGCATT CTAAATGAAG ATGTAAACAT AGGCAGCAAC ACTCAAGAGT AAAAATGAAG 1320
TGTGCATATG AAAGAAACCT ATTCACATGG ACCATATTAC ATTATAATCA CAGTGTTTAC 1380
TGCTTGACTA CCATCTGCCT GGGCTAGCAA GGGTGTCACT GAGGAAGAGA GGACAAGGGG 1440
TACCAATCTG TGAACATAC ATGGTTCTTG CTCTCCCAGC TTCTCTCTCC CATTGGCAAG 1500
GCAACAGGTA AACACATGAA AAATCAAATA ATGCTATAAG AGAAAAATGT ATTCAGGACA 1560
ACAACAGGTT TGTATGAAGG CCTTTCATCA TCGTTGTCCT ACCTAGAAAC TGAATGACAG 1620
GGAATCAGAG TCACAAGCTA TGAAGTCTAA CTGGGCTGGT CCCAGAGAAA GATTCACTGC 1680
AGTAGGTGGG GCTGCAGCCA GCCCTGGGTG GGTGGAAGGA TGACATCCAC ATAGGCAAGA 1740
GGGTGATAAT TCACCTGCGC AGCTCCTCAC TGCACATTGA ACCCTGCTGA CTTCTGGCTT 1800
CTCTCCCGGG AGGAACTGCG ACTCAACATT CTGACCTTAT CTCTTGGGTA GCAGAAATGAT 1860
GGAGAAGGAA AGTTTCTTTT TGCTTCTCGC AGGGGTTAAT CATCCATCTG GAATGCCTAC 1920
ATTTGGTTGA CAATGGCTCA CCCTATCATC TTCCTCCTGA ACCATTCAAC TAAATGTGCC 1980
ATTTCTTTCC TGATAGTTCT CATTTGTGTG TGTGTGTGTG TGTGTGTGTG TGCACGTGCT 2040
CACACATGCA TGCTGTCACT GGGTAAACAG GCCACCCTGG GCACAGTTCC ATCTACAATG 2100
TTTGAAGTTT ACTTTCCAGC TTCTGGGCAT CATTTGCAAT TATAATGCTG TCACAGGCAG 2160
AAACGAGATA GGCTAATTAA TCGTTGTCAA TACTGATCCC TATTTGCCAG ATGAGATTTT 2220
GGAGCAGCAT GGCTGGGAAT AATTGGTATA GACTGTATTT CCTTGCTTTA TGTCAGTGGA 2280
AATATTTATT TAAGCATCAC GGTGCTATG CATAAATATC CTGGAAAATG GGGTATAGCT 2340
GAATGGTGCA GATTCATTCA TTCATATTCA GCAAATTATG TTCTAAGCAC CTACTTCAGT 2400
ACGTGAACAG CACTAACTC AGAATATTGG TCTGCTGGGG TCCTTTATTA GCTTCCATGA 2460
TTCCCTGAAC TTGGCCAAGA CCCTTCTGGT CGGCTGCAGA TAGGCACAAT GGATAGTTTT 2520
GCTTCTAGA 2529

- 62 -

I CLAIM

1. A recombinant DNA molecule adapted for transfection of a host cell comprising a nucleic acid molecule encoding mammalian erythropoietin, an expression control sequence
5 operatively linked thereto and at least one SAR element.
2. A recombinant DNA molecule as claimed in claim 1 wherein the nucleic acid molecule encodes human erythropoietin.
3. A recombinant DNA molecule as claimed in claim 2
10 wherein the nucleic acid molecule encodes erythropoietin having the amino acid sequence shown in SEQ ID NO 34.
4. A recombinant DNA molecule as claimed in claim 3 wherein the nucleic acid molecule has the sequence as shown in SEQ ID NO. 35.
- 15 5. A recombinant DNA molecule as claimed in claim 1 wherein the SAR element is a SAR element which co-maps with a chromatin domain boundary.
6. A recombinant DNA molecule as claimed in claim 5 wherein the SAR element is a human apolipoprotein SAR
20 element.
7. A recombinant DNA molecule as claimed in claim 5 wherein the SAR element comprises the sequence as shown in SEQ ID NO. 36 or 37.
8. A recombinant DNA molecule as claimed in claim 1
25 wherein the nucleic acid molecule encoding mammalian erythropoietin and the expression control sequence operatively linked thereto are flanked by SAR elements.
9. An expression vector comprising a recombinant DNA molecule as claimed in claim 1.

- 63 -

10. An expression vector comprising a nucleic acid molecule encoding erythropoietin and having the sequence shown in SEQ ID NO. 35 under the control of a promoter, flanked by 5' and 3' apolipoprotein SAR elements.
- 5 11. An expression vector as claimed in claim 10 wherein the promoter is a human cytomegalovirus IE enhancer and promoter, or an elongation factor-1 alpha promoter.
12. A mammalian cell transformed with an expression vector as claimed in claim 9.
- 10 13. A mammalian cell lacking a selectable gene capable of being amplified, said cell being capable of expressing recombinant EPO in vitro at levels of at least 2,000 u/10⁶ cells in 24 hours.
14. A method of expressing recombinant mammalian erythropoietin comprising the steps of culturing a
15 mammalian cell as claimed in claim 13 in a suitable medium until sufficient amounts of erythropoietin are produced by the cell and separating the erythropoietin produced.
15. A method of preparing recombinant erythropoietin
20 comprising transfecting a mammalian cell with an expression vector comprising a recombinant DNA molecule as claimed in claim 1, and culturing the transfected cell in a suitable medium until sufficient amounts of erythropoietin are produced by the cell and separating the
25 erythropoietin produced.
16. A method as claimed in claim 14 wherein the mammalian cell is further transfected with a selectable marker gene and wherein transfected cells are selected by means of the selectable marker gene.
- 30 17. A method as claimed in claim 16 wherein the


- 64 -

selectable marker gene is neo.

18. A method as claimed in claim 14 comprising the additional step of identifying and selecting cells producing high levels of erythropoietin; subcloning the
5 selected cells; establishing long term cell lines from the selected cells and; culturing the selected cells in a suitable medium until sufficient amounts of erythropoietin are produced by the cell and separating the erythropoietin produced.
- 10 19. A method as claimed in claim 14 wherein erythropoietin is produced at levels of at least 1,500 u/10⁶ cells in 24 hours in the absence of gene amplification.
20. Erythropoietin produced by the method of claim 14.
- 15 21. A transgenic non-human animal or embryo whose germ cells and somatic cells contain a DNA construct comprising the recombinant DNA molecule as claimed in claim 1.

1/15

FIGURE 1A



SUBSTITUTE SHEET

2/15

FIGURE 1B

OLIGONUCLEOTIDE	SEQUENCE	SEQUENCE POSITION (as per AMGEN patent cDNA)
EPO1	5'- AGC TTG CCC GGG ATG AGG GCC ACC GGT GTG GTC ACC CGG CGC GCC CCA GGT	111 - 153
EPO2	5'- CGC TGA GGG ACC CCG GCC AGG CGC GGA GAT GGG GGT GCA CGA AT	154 - 197
EPO3	5'- CTC CTG CCT GGC TGT GGC TTC TCC TGT CCC TGC TGT CGC TCC CTC TGG GCC	198 - 248
EPO4	5'- TCCC CAG TCC TGG GCG CCC CAC CAC GCC TCA TCT GTG ACA GCC GAG TCC TGG AGA GGT AC	249 - 307
EPO5	5'- CTC TTG GAG GCC AAG GAG GCC GAG AAT ATC ACG ACG GGC TGT GCT GAA CAT TGC AG	308 - 363
EPO6	5'- CTT GAA TGA GAA TAT CAC TGT CCC AGA CAC CAA AGT TAA TTT CTA TGC CTG GAA GAG G	364 - 421
EPO7	5'- ATG GAG GTC GGG CAG CAG GCC GTA GAA GTC TGG CAG GGC CTG GCC CTG CTG TCG G	422 - 476

SUBSTITUTE SHEET

3/15

FIGURE 1B (Cont'd)

EPO8	5'-AAG CTG TCC TGC GGG GCC AGG CCC TGT TGG TCA ACT CTT CCC AGC CGT GGG AGC CCC TGCA	477 - 537
EPO9	5'-GCT GCA TGT GGA TAA AGC CGT CAG TGG CCT TCG CAG CCT CAC CAC TCT GCT TCG	538 - 591
EPO10	5'-GGC TCT GGG AGC CCA GAA GGA AGC CAT CTC CCC TCC AGA TGC GGC CTC AGC	592 - 642
EPO11	5'-TGC TCC ACT CCG AAC AAT CAC TGC TGA CAC TTT CCG CAA ACT CTT CCG AGT	643 - 693
EPO12	5'-CTA CTC CAA TTT CCT CCG GGG AAA GCT GAA GCT GTA CAC AGG GGA GG	694 - 740
EPO13	5'-CCT GCA GGA CAG GGG ACA GAT GAC CAG GTG TGT CGA CCT GGG CAT ATC	741 - 788
EPO13b	5'-CCT GCA GGA CAG GGG ACA GAT GAC CAG GTG TGT CCA CCT GGG CAT ATC	741 - 788
EPO14	5'-CAC CAC CTC CCT CAC CAA TAT TGC TTG TGC CAC ACC CTC CCC CGC CAC TC	789 - 838

SUBSTITUTE SHEET

4/15

FIGURE 1B (Cont'd)

EPO15	5'-CTG AAC CCC GTC GAG GGG CTC TCA GCT CAG CGC CAG CCT GTC CCA TGG ACC A	839 - 888
EPO1 α	5'-CCT CAG CGA CCT GGG GCG CGC CGG GTG ACC ACA CCG GTG GCC CTC ATC CCG GGC A	111 - 161
EPO2 α	5'-GGC AGG ACA TTC GTG CAC CCC CAT CTC CGC GCC TGG CCG GGG TC	162 - 205
EPO3 α	5'-GGA CTG GGA GGC CCA GAG GGA GCG ACA GCA GGG ACA GGA GAA GCC ACA GCC A	206 - 257
EPO4 α	5'-CTC TCC AGG ACT CCG CTG TCA CAG ATG AGG CGT GGT GGG GCG CCC A	258 - 303
EPO5 α	5'-TTC AGC ACA GCC CGT CGT GAT ATT CTC GGC CTC CTT GGC CTC CAA GAG GTA C	304 - 355
EPO6 α	5'-AGG CAT AGA AAT TAA CTT TGG TGT CTG GGA CAG TGA TAT TCT CAT TCA AGC TGC AAT G	356 - 413
EPO7 α	5'-AGG GCC AGG CCC TGC CAG ACT TCT ACG GCC TGC TGC CCG ACC TCC ATC CTC TTC C	414 - 468

SUBSTITUTE SHEET

5/15

FIGURE 1B (Cont'd)

EPO8 α	5'- GGG GCT CCC ACG GCT GGG AAG AGT TGA CCA ACA GGG CCT GGC CCC GCA GGA CAG CTT CCG ACA GC	469 - 533
EPO9 α	5'- AGT GGT GAG GCT GCG AAG GCC ACT GAC GGC TTT ATC CAC ATG CAG CTG CA	534 - 583
EPO10 α	5'- CGC ATCTGG AGG GGA GAT GGC TTC CTT CTG GGC TCC CAG AGC CCG AAG CAG	584 - 634
EPO11 α	5'- AGA CTC GGA AGA GTT TGC GGA AAG TGT CAG CAG TGA TTG TTC GGA GTG GAG CAG CTG AGG C	635 - 695
EPO12 α	5'- CCT GCA GGC CTC CCC TGT GTA CAG CTT CAG CTT TCC CCG GAG GAA ATT GGA GT	696 - 748
EPO13 α	5'- GGT GGT GGA TAT GCC CAG GTC GAC ACA CCT GGT CAT CTG TCC CCT GT	749 - 795
EPO13b α	5'- GGT GGT GGA TAT GCC CAG GTG GAC ACA CCT GGT CAT CTG TCC CCT GT	749 - 795
EPO14 α	5'- GGG TTC AGG AGT GGC GGG GGA GGG TGT GGC ACA AGC AAT ATT GGT GAG GGA	796 - 846

SUBSTITUTE SHEET

6/15

847 - 888

FIGURE 1B (Cont'd)


5'-AGC TTG GTC CAT GGG ACA GGCTGG CGC
TGA GCT GAG AGC CCC TCG ACC

EPO15a

SUBSTITUTE SHEET

7/15

FIGURE 2A



SUBSTITUTE SHEET


8/15

FIGURE 2B

Figure 2B: Schematic for assembly of EPO_{long}

EPO BLOCK 4b

-in puc18 @ HincII



SUBSTITUTE SHEET

9/15

FIGURE 3A

```

1  aagcttctg gcttccagac ccagctactt tgcggaactc agcaaccagc gcattctctga
61  gtctccgccc aagaccggga tgccccccag gggaggtgtc cgggagccca gcctttccca
121 gatagcacgc tccgccagtc ccaagggtgc gcaaccggct gcaactccct cccgcgaccc
181 agggcccggg agcagccccc atgaccacac cgcacgtctg cagcagcccc gctcacgccc
241 cggcgagcct caaccacagg gtcctgcccc tgctctgacc ccgggtggcc cctacccttg
301 gcgaccctc acgcacacag cctctcccc acccccaccc gcgcacgcac acatgcagat
361 aacagccccc acccccggcc agagccgcag agtccctggg ccaccctggc cgctcgctgc
421 gctgcgccc accgcgctgt cctcccggag ccggaccggg gccaccgcgc ccgctctgct
481 ccgacaccgc gccccctgga cagccgcctt ctctctagg ccctgtgggg tggccctgca
541 ccgcccagct tccccggatg agggccccc gtgtggtcac ccggcgcgcc ccaggtcgct
601 gagggacccc ggccaggcgc ggagatggg gtgcacggtg agtactcgcg ggctggggcg
661 tcccgccgce cgggtccctg tttgagcggg gatttagcgc cccggctatt ggccaggagg
721 tggctggggt caaggaccgg cgaactgtca aggaccccg aagggggagg ggggtggggc
781 agcctccacg tgccagcggg gacttggggg agtccctggg gatggcaaaa acctgacctg
841 tgaaggggac acagtttggg ggttgagggg aagaaggttt gggggttctg ctgtgccagt
901 ggagaggaag ctgataagct gataacctgg gcgctggagc caccattat ctgccaggag
961 ggaagcctct gtcacaccag gattgaagtt tggccggaga agtggtatgt ggtagctggg
1021 ggtggggtgt gcacacggca gcaggattga atgaaggcca gggaggcagc acctgagtgc
1081 ttgcatggtt ggggacagga aggacgagct ggggagaga cgtggggatg aaggaaagctg
1141 tccctccaca gccacccttc tccctcccg cctgactctc agcctggcta tctgttctag
1201 aatgtcctgc ctggctgtgg cttctcctgt cctgtctgtc gctccctctg ggccctccag
1261 tccctggggc cccaccacgc ctcactgttg acagccgagt cctggagagg tacctcttgg
1321 aggccaaagg ggccgagaat atcacggtga gacccttcc ccagcacatt ccacagaact
1381 cagctcagg gcttcaggga actcctccca gatccaggaa cctggcactt ggtttggggg
1441 ggagttggga agctagacac tgcccccta cataagaata agtctgggtg ccccaaacca
1501 tacctggaaa ctaggcaagg agcaaagcca gcagatccta cggcctgtgg gccaggggca
1561 gagccttcag ggacccttga ctccccgggc tgtgtgcatt tcagacgggc tgtgtgaac
1621 actgcagctt gaatgagaat atcactgtcc cagacaccaa agttaatttc tatgcctgga
1681 agaggatgga ggtgagttcc tttttcttt ttttctctt cttttggaga atctcatttg
1741 cgagcctgat tttggatgaa agggagaatg atcgggggaa aggtaaaaat gagcagcaga
1801 gatgaggctg cctgggcgca gaggctcacg tctataatcc caggctgaga tggccgagat
1861 gggagaattg cttgagccct ggagtttcag accaacctag gcagcatagt gagatcccc
1921 atctctacaa acatttataa aaattagtca ggtgaagtgg tgcatggtgg tagtcccaga
1981 tatttggaa gctgaggcgg gaggatcgct tgagcccagg aatttgaggc tgcagtgagc
2041 tgtgatcaca ccactgcact ccagcctcag tgacagagtg aggccctgtc tcaaaaaaga
2101 aaagaaaaaa gaaaaataat gagggctgta tggatacat tcattattca ttcactcact
2161 cactcactca ttcattcatt cattcattca acaagtctta ttgcatacct tctgtttgct
2221 cagcttggtg cttggggctg ctgaggggca ggagggagag ggtgacatgg gtcagctgac
2281 tcccagagtc cactccctgt aggtcgggca gcaggccgta gaagtctggc agggcctggc
2341 cctgtctgtc gaagctgtcc tgccggggcca ggccctgttg gtcaactctt cccagccgtg
2401 ggagcccttg cagctgcagtg tggataaagc cgtcagtggc cttcgagcc tcaccactct
2461 gcttcgggct ctgggagccc aggtgagtag gagcggacac ttctgcttgc cctttctgta
2521 agaagggggag aagggtcttg ctaaggagta caggaactgt ccgtattcct tccctttctg
2581 tggcactgca gcgacctcct gttttctcct tggcagaagg aagccatctc cctccagat
2641 gcggcctcag ctgctccact ccgaacaatc actgctgaca ctttccgcaa actcttccga
2701 gtctactcca atttctccg gggaaagctg aagctgtaca caggggaggc ctgcaggaca
2761 ggggacagat gaccaggtgt gtccactcgg gcatatccac cacctccctc accaaccattg
2821 cttgtgccac accctcccc gccactcctg aaccccgctc aggggctctc agctcagcg
2881 cagcctgtcc catggacact ccagtccag caatgacatc tcaggggcca gaggaactgt
2941 ccagagagca actctgagat ctaaggatgt cacagggcca acttgagggc ccagagcagg
3001 aagcattcag agagcagctt taaactcagg gacagagcca tgctgggaag acgctgagc
3061 tcaactcgga ccctgcaaaa tttgatgcca ggacacgctt tggaggcag ttacctgttt
3121 tcgcacctac catcaggggac aggatgacct ggagaactta ggtggcaagc ccccttgac accggggtgg
3181 ccaggctcga cgggcatggg cactcccttg gtggcaagag ccccttgac caagttttgt
3241 tgggaaccca gaagacagga tgggggctgg cctctggctc tcatggggtc gcttttctgt
3301 gtattcttca acctcattga caagaactga aaccaccaat atgactcttg gcttttctgt
3361 tttctgggaa cctccaaatc ccctggctct gtcccactcc tggcagcagt gcagcagtc
3421 caggtccggg aaatgagggg tggagggggc tgggccctac gtgctgtctc acacagcctg
3481 tctgacctct cgacctaccg gcctaggcca caagctctgc ctacgctggt caataagggtg
3541 tctccattca aggectcacc gcagtaaggc agctgccaac cctgcccagg gcaaggctgc
3601 ag

```

SUBSTITUTE SHEET

10/15

FIGURE 3B

MGVHECPAWLWLLLSLLSLPLGLPVLGAPPRLICDSRVLERYLLEAKEAENITTGCAEHC
SLNENITVPDTKVNIFYAWKRMEVGQQAVEVWQGLALLSEAVLRGQALLVNSSQPWEPLQL
HVDKAVSGLRSLTTLRALGAQKEAISPPDAASAAPLRTITADTFRKLFRVYSNFLRGKL
KLYTGEACRTGDR

SUBSTITUTE SHEET

11/15

FIGURE 4

AGCTTGCCCC GGATGAGGGC CACCGGTGTG GTCACCCGGC GCGCCCCAGG TCGCTGAGGG 60
ACCCCGGCCA GCGCGGAGA TGGGGGTGCA CGAATGTCCT GCCTGGCTGT GGCTTCTCCT 120
GTCCCTGCTG TCGCTCCCTC TGGGCCTCCC AGTCCTGGGC GCCCCACCAC GCCTCATCTG 180
TGACAGCCGA GTCCTGGAGA GGTACCTCTT GGAGGCCAAG GAGGCCGAGA ATATCACGAC 240
GGGCTGTGCT GAACATTGCA GCTTGAATGA GAATATCACT GTCCCAGACA CCAAAGTTAA 300
TTTCTATGCC TGAAGAGGA TGGAGGTCGG GCAGCAGGCC GTAGAAGTCT GGCAGGGCCT 360
GGCCCTGCTG TCGGAAGCTG TCCTGCGGGG CCAGGCCCTG TTGGTCAACT CTTCCCAGCC 420
GTGGGAGCCC CTGCAGCTGC ATGTGGATAA AGCCGTCAGT GGCCTTCGCA GCCTCACCAC 480
TCTGCTTCGG GCTCTGGGAG CCCAGAAGGA AGCCATCTCC CCTCCAGATG CGGCCTCAGC 540
TGCTCCACTC CGAACAATCA CTGCTGACAC TTTCCGCAA CTCTTCCGAG TCTACTCCAA 600
TTTCCTCCGG GGAAAGCTGA AGCTGTACAC AGGGGAGGCC TGCAGGACAG GGGACAGATG 660
ACCAGGTGTG TCCACCTGGG CATATCCACC ACCTCCCTCA CCAATATTGC TTGTGCCACA 720
CCCTCCCCCG CCACTCCTGA ACCCCGTCGA GGGGCTCTCA GCTCAGCGCC AGCCTGTCCC 780
ATGGACCA

SUBSTITUTE SHEET

12/15

FIGURE 5

1 AAAAAGATGA GGTAATTGTG TTTTATAAT TAAATATTTT ATAATTAAAA TATTTATAAT
TTTTTCTACT CCATTAACAC AAAAATATTA ATTTATAAAA TATTAATTTT ATAAATATTA

61 TAAAATATTT ATAATTAAAT ATTTTATAAT TAAAATATTT ATAATTAAAT ATTTTATAAT
ATTTTATAAA TATTAATTTA TAAAATATTA ATTTTATAAA TATTAATTTA TAAAATATTA

121 TAAAATATTT ATAATTAAAT ATTTTATAAT TAAAATATTT ATAATTAAAT ATTTTATAAT
ATTTTATAAA TATTAATTTA TAAAATATTA ATTTTATAAA TATTAATTTA TAAAATATTA

181 TAAAATATTT ATAATTAAAT ATTTTATAAT TAAAATATTT ATAATTAAAT ATTTTATAAT
ATTTTATAAA TATTAATTTA TAAAATATTA ATTTTATAAA TATTAATTTA TAAAATATTA

241 TAAAATATTT ATAATTAAAT ATTTTATAAT TAAAATGTTT ATAATTAAAT ATTTTATAAT
ATTTTATAAA TATTAATTTA TAAAATATTA ATTTTACAAA TATTAATTTA TAAAATATTA

301 TAAAATGTTT ATAATTACAT ATTTTATAAT TAAAATGTTT ATAATTACAT ATTTTATAAT
ATTTTACAAA TATTAATGTA TAAAATATTA ATTTTACAAA TATTAATGTA TAAAATATTA

361 TAAAATGTTT ATAATTACAT ATTTTATAAT TAAAATGTTT ATAATTACAT ATTTTATAAT
ATTTTACAAA TATTAATGTA TAAAATATTA ATTTTACAAA TATTAATGTA TAAAATATTA

421 TAAAATGTTT ATAATTACAT ATTTTATAAT TACATATTTT ATAAAGTATT TATAATTACA
ATTTTACAAA TATTAATGTA TAAAATATTA ATGTATAAAA TATTCATAA ATATTAATGT

481 TATTTTATAA TTAAAGTATT TATAATTACA TATTTTATAA TTAAAGTATT TATAATTACA
ATAAATATT AATTCATAA ATATTAATGT ATAAATATT AATTCATAA ATATTAATGT

541 TATTTTATAA TTCAATATTT TATAAATAGT TAAAAAGACG AGGAAAAAAT TAAAAAGACG
ATAAATATT AAGTTATAAA ATATTTATCA ATTTTCTGCTC TCCTTTTTTA ATTTTCTGCTC

601 AGGTTATTGA TCTCAGGAAT TGTATTTGCC AAGTGAGAAG GAAAAAATAT TCACAAAGGC
TCCAATAACT AGAGTCCTTA ACATAAACGG TTCACTCTTC CTTTTTTATA AGTGTTTCCG

661 TTGTA
AACAT

SUBSTITUTE SHEET

13/15

FIGURE 6

```


1 TCTAGACCCC AGTTTCTCTA TAAGATGAGA ATATTAGTCA CGATTGTTGTT TCTAAGATCC
61 TGTCTATGTT TGAGACTACA GATACCTGTT GCTACATTTC CCTTCATAGC TCTGAACAAG
121 GAGAATTCAG CCCAATTCTC ATGGCCTTCT AAACAATCCA GAGTTTCAGT GCCATAAGGT
181 ACTACAATTT AGTGTCAAAT TAAGTCAAAG GCTTCATTAG CCTGAAAGCT CTGTCCCTGG
241 CCTGGGCATG GCAAAGTGTG TCCCCCACTG ACCATCCCCC TGTCTCCCTT CTCCCCAGAG
301 ACTCCAGTAG CCTGGCGTCA TCACAGGGGC CAGACATATC CAACATGTTT CCAGCTTCCT
361 GCCACTTGAC TTTCAGTGTG CCTCCCTCTT CAGTTACCCA AATCCTGCCC ACCATTCCAG
421 AGCCAGTTCA ATCTCACCCA TCCAGGACCC CCGAGACCCC CATCGTACCA CTATAGTCTA
481 ACTGTGGTGT AGACCCACACA CTGGGCACAT TGCCTACGCT CATTATTGGC TGTGACGTCT
541 GATTATGCCC TTCTCCTGGT CTGGAAGCTC TCGGAGGTGC TCCATAATAC ATGAAGAGAA
601 GTAGTGCTGG TGTGGGAATA GTGAGGTGTG TTTATCCATC CAGCTATCCG GCACCAGCAC
661 TGGTCTCAGC TTTCTGAGGT AACACGTTCT GAGCCTTAGT CTTGAGAGAA CATAAAGAAA
721 ACTTTTTTTA AAAGTAGTAA AAAGTGGCTG ACAAAGCTG ACCAAAAGCC TTCAAAAGAA
781 ATGCTAAGTT ATATCTAAGA AAGTTTACCC AAGGTCAGGC AAATATGAAA CCTAAAGCTA
841 GACGTGGGGA AGAACTCCG GAGAGTTGCA ATTCCCTGTG CCCCAGCATC CCCAGGAGGG
901 CATGCCCCACA TCTGATTTAG AAATCTGTGT AAAATGAGTG AAGGTTTCTA TTTCTTGGGC
961 AGTGTGGGCA CAGGTCTTTG GAGAGGTGCA TGGCCTCCCA TAAAATCCTT CCTGCTTGAT
1021 GGTCTGGAT CCTCAGCCAC AGCTCCTAAT AGCCATGAGG TTTGAGCCCA AAATAATTTA
1081 TGTGTTTGT TTTTCAGCCC CAAAATTTCC ATAGAATCAA AGTAGTCAGA GCTGAATGGG
1141 GCTAAGAGAC CGTCCATTCC TGTCTTCTCA TCACAGATGA GGGACTGCCA CCCAGAGCCG
1201 TAGAACTGT CCCATGGCCC CAGTTCCAG ACCCTTCTC TCTCCTACAG CTCCAAGTTC
1261 ACTGTGCATT CTAAATGAAG ATGTAAACAT AGGCAGCAAC ACTCAAGAGT AAAAATGAAG
1321 TGTGCATATG AAAGAAACCT ATTCACATGG ACCATATTAC ATTATAATCA CAGTGTTTAC
1381 TGCTTGACTA CCATCTGCCT GGGCTAGCAA GGGTGTGAGT GAGGAAGAGA GGACAAGGGG
1441 TACCAATCTG TGAACACAC ATGGTTCTTG CTCTCCAGC TTCTCTCTCC CATTGGCAAG
1501 GCAACAGGTA AACACATGAA AAATCAAATA ATGCTATAAG AGAAAAATGT ATTCAAGACA
1561 ACAACAGGTT TGATGAAGG CTTTTCATCA TCGTTGTCCT ACCTAGAAAC TGAATGACAG
1621 GGAATCAGAG TCACAAGCTA TGAAGTCTAA CTGGGCTGGT CCCAGAGAAA GATTCAAGTGC
1681 AGTAGGTGGG GCTGCAGCCA GCCCTGGGTG GGTGGAAGGA TGACATCCAC ATAGGCAAGA
1741 GGGTGATAAT TCACTTGCGC AGCTCCTCAC TGCACATTGA ACCCTGCTGA CTTCTGGCTT
1801 CTCTCCCGGG AGGAACTGCG ACTCAACATT CTGACCTTAT CTCTTGGGTA GCAGAATGAT
1861 GGAGAAGGAA AGTTTCTTTT TGCTTCTCGC AGGGGTAAAT CATCCATCTG GAATGCCATC
1921 ATTTGGTTGA CAATGGCTCA CCCTATCATC TTCTCTCTGA ACCATTACCC TAAATGTGCC
1981 ATTTCTTTCC TGATAGTTCT CATTGTGTGT TGTGTGTGTG TGTGTGTGTG TGCACGTGCT
2041 CACACATGCA TGCTGTCACT GGGTAAACAG GCCACCCTGG GCACAGTTCC ATCTACAATG
2101 TTTGAAGTTT ACTTTCCAGC TTCTGGGCAT CATTGTGCAAT TATAATGCTG TCACAGGCAG
2161 AAACGAGATA GGCTAATTAA TCGTTGTCAA TACTGATCCC TATTTGCCAG ATGAGATTTT
2221 GGAGCAGCAT GGCTGGGAAT AATTGGTATA GACTGTATTT CCTTGCTTTA TGTCACTGGA
2281 AATATTTATT TAAGCATCAC GGTCGCTATG CATAAATATC CTGGAAAATG GGGTATAGCT
2341 GAATGGTGCA GATTCAATTCA TTCATATTCA GCAAATTATG TTCTAAGCAC CTACTTCAGT
2401 ACGTGAACAG CACTAAACTC AGAATATTGG TCTGCTGGGG TCCTTTATTA GCTTCCATGA
2461 TTCCCTGAAC TTGGCCAAGA CCCTTCTGGT CGGCTGCAGA TAGGCACAAT GGATAGTTTT
2521 GCTTCTAGA

```

SUBSTITUTE SHEET

14/15


FIGURE 7



SUBSTITUTE SHEET

15/15

FIGURE 8



SUBSTITUTE SHEET

INTERNATIONAL SEARCH REPORT

Int. Application No
PCT/CA 95/00696

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C12N15/67 C12N15/85 C12N5/10 C07K14/505
A01K67/027

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ANN. N.Y. ACAD. SCI., VOL. 665 (BIOCHEM. ENG. VII), 1992 pages 127-136, E.I. TSAO ET AL. 'Optimization of a roller bottle precess for the production of recombinant erythropoietin' see the whole document ---	20
X	PROC. NATL. ACAD. SCI., vol. 82, November 1985 NATL. ACAD. SCI., WASHINGTON, DC, US;, pages 7580-7584, F.-K. LIN ET AL. 'Cloning and expression of human erythropoietin gene' see the whole document --- -/--	20

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "A" document member of the same patent family

Date of the actual completion of the international search

29 March 1996

Date of mailing of the international search report

02.04.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Hornig, H

INTERNATIONAL SEARCH REPORT

Inte nal Application No
PCT/CA 95/00696

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,86 03520 (GENETICS INST) 19 June 1986 cited in the application see the whole document ---	20
A	MOL. CELL. BIOL., vol. 10, no. 3, March 1990 ASM WASHINGTON, DC,US, pages 930-938, G.L. SEMENZA ET AL. 'Human erythropoietin gene expression in transgenic mice: Multiple transcription initiation sites and cis-acting regulatory elements' see the whole document ---	21
A	J. BIOL. CHEM., vol. 264, no. 15, 15 December 1989 AM. SOC. BIOCHEM. MOL.BIOL.,INC.,BALTIMORE,US, pages 21196-21204, B. LEVY-WILSON AND C. FORTIER 'The limits of the DNaseI-sensitive domaine of the human apolipoprotein B gene coincide with the locations of chrmosomal anchorage loops and define the 5' and 3' boundaries of the gene' cited in the application see the whole document ---	1-21
A	BIOCHEMISTRY, vol. 30, no. 5, 5 February 1991 AM. CHEM. SOC.,WASHINGTON,DC,US, pages 1264-1270, D. KLEHR ET AL. 'Scaffold-attched regions from the human interferon beta can be used to enhance the stable expression of genes under the control of various promoters' cited in the application see the whole document ---	1-21
A	MOL. CELL. BIOL., vol. 10, no. 5, May 1990 ASM WASHINGTON, DC,US, pages 2305-2307, L. PHI-VAN ET AL. 'The chicken lysozyme 5' attachment region increases transcription from a heterologous promoter in heterologous cells and dampens position effects on the expression of transfected genes' cited in the application see the whole document ---	1-21
2		
2	P,A WO,A,95 20653 (AGRONOMIQUE INST NAT RECH) 3 August 1995 see the whole document -----	21

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 95/00696

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-8603520	19-06-86	AU-B- 621535	19-03-92
		AU-B- 5313486	01-07-86
		DE-A- 3585161	20-02-92
		EP-A,B 0205564	30-12-86
		EP-A- 0411678	06-02-91
		JP-A- 1257480	13-10-89
		JP-B- 6055144	27-07-94
		JP-A- 2104284	17-04-90
		JP-A- 2000442	05-01-90
		JP-A- 6189758	12-07-94
		JP-A- 7184681	25-07-95
		JP-B- 1044317	27-09-89
		JP-T- 62501010	23-04-87
		LT-A- 1481	26-06-95
		SG-A- 93993	25-02-94
		SG-A- 94093	25-02-94
		SU-A- 1672930	23-08-91
		SU-A- 1801118	07-03-93
WO-A-9520653	03-08-95	FR-A- 2715665	04-08-95
		AU-B- 1581995	15-08-95